

ANNUAL REPORT 2003

PAREXEL®

Financial Highlights


Fiscal Year Ended June 30

IN THOUSANDS EXCEPT PER SHARE DATA


	2003	2002	2001
Service revenue			
Clinical Research Services	\$312,847	\$261,727	\$240,501
PAREXEL Consulting Group	\$100,621	\$ 97,775	\$ 80,796
Medical Marketing Services	\$ 73,786	\$ 64,829	\$ 54,277
Perceptive Informatics, Inc.	\$ 24,800	\$ 19,987	\$ 11,986
Total service revenue	\$512,054	\$444,318	\$387,560
Net income (loss)	\$ 10,662	\$ 13,235	\$ [825]
Diluted earnings (loss) per share	\$ 0.42	\$ 0.52	\$ [0.03]
Working capital	\$134,346	\$138,020	\$123,488
Total assets	\$464,237	\$407,161	\$361,534
Stockholders equity	\$227,100	\$200,077	\$177,822

Segment Information

Fiscal Year 2003




Service Revenue



Geographic Mix

Fiscal Year 2003



DEAR SHAREHOLDERS:


The true test of any organization is how well it can execute its business strategy – how well the organization turns ideas into plans, plans into actions, and actions into accomplishments. Execution is crucial, because nothing says more about a company's long-term ability to thrive and deliver profitable growth. By that yardstick, Fiscal Year 2003 was a successful year for PAREXEL. We realized solid progress, strategically, financially and operationally, in executing our goals for Fiscal Year 2003.

FINANCIAL HIGHLIGHTS

Once again, PAREXEL achieved record service revenue, finishing the year with net revenue of \$512.1 million, an increase of 15.3% over \$444.3 million in Fiscal Year 2002. Operating income was \$20.6 million, or 4.0% of consolidated net service revenue, compared with \$20.5 million, or 4.6% of consolidated net service revenue in the prior year. On a proforma basis, excluding facilities-related restructuring charges, operating income was approximately \$30 million, or 5.9% of revenue.* Also, I would like to note that operating cash flow in Fiscal Year 2003 totaled \$47.8 million, an increase of 114% from Fiscal Year 2002. I am particularly pleased that we ended the Fiscal Year with \$82.7 million in cash.

During Fiscal Year 2003, three of our four business units achieved double-digit year-over-year revenue growth. Revenue in Clinical Research Services (CRS) grew by 19.5% year-over-year. CRS was the largest contributor to the Company's overall revenue and delivered the biggest growth in gross profit margin. The CRS management team also improved performance in several other key areas – quality, project performance, and customer satisfaction. We believe that CRS is well positioned for market share gains in an expanding market.

Another of the Company's notable achievements was the 13.8% year-over-year revenue growth in Medical Marketing Services (MMS). We anticipate MMS opportunities will increase as a result of pressure



JOSEF H. VON RICKENBACH

Chairman of the Board and Chief Executive Officer

on clients to have their new products reach peak sales faster and the additional complexities of the purchasing process for new drugs as it relates to payers, patients, and medical professionals.

On another front, we believe that the expanded portfolio of products now offered by Perceptive Informatics provides increased growth opportunities, as demonstrated by Perceptive's 24% year-over-year revenue growth. Perceptive has achieved a solid reputation as a leader in clinical research management-related technologies. Our strategic plans call for us to offer several additional applications beyond those we currently sell and support.

This year, we experienced a business downturn in the PAREXEL Consulting Group (PCG), resulting in revenue growth for that unit of only 2.9% compared with the prior year. One segment of the PCG business, Clinical Pharmacology, did very well due to increased market demand for Phase I services and increased utilization of our Phase I units. The challenges occurred in the manufacturing compliance/validation and management consulting businesses, which were negatively impacted by a marked slowdown in enforcement activity by the Food and Drug Administration (FDA) and a reduction in discretionary spending by bio/pharmaceutical clients for consulting projects. In recent months, we have revamped the PCG sales model, developed new service offerings, and streamlined the organization. We expect to see gradual improvement in PCG's overall performance during Fiscal Year 2004 as a result of these changes.

In June 2001, we took a restructuring charge in conjunction with a decision to consolidate office space in a number of facilities. At that time, we made certain assumptions regarding the timing of sub-leases and related rental rates for these facilities. Unfortunately, a deterioration in the commercial real estate market prevented us from realizing certain parts of our original space consolidation plan. So, in accordance with SFAS 146, we took a charge in the second quarter of

* As reported operating income of \$20.6 million plus \$9.4 million of charges equals proforma operating income of \$30 million.

Fiscal Year 2003 to reflect changes to our original assumptions. An additional charge was recorded in the fourth quarter of Fiscal Year 2003 to reflect further deterioration in real estate market conditions. Recently, we have had increased interest in our available space and have been able to sublease portions of it. We hope this issue is now behind us.

Fiscal Year 2003 saw a bit of a shift with regard to the geographic mix of revenue. As reflected in our strategy, we have long believed that the Company's sizeable global footprint gives us the ability to conduct and manage international trials, enhances our value to clients, and offers opportunities for optimal patient recruitment. This year the Americas accounted for 52% of our service revenue versus 57% in Fiscal Year 2002; Europe grew from 39% in Fiscal Year 2002 to 44% in Fiscal Year 2003; and Asia/Pacific held steady at 4% of revenue. We were especially pleased with the improved performance in Europe, which was derived primarily from the combination of effective management, improved productivity and increased work on global contracts involving large patient populations in Europe.

Our purchase of a minority share in APEX International Clinical Research Co. Ltd., a leading Asian CRO with operations in Taiwan, Korea, China, Hong Kong, Singapore, Malaysia, Thailand, and Australia, has further enhanced our global reach. APEX, and its strong Asian investigator network, has expanded our capability to pursue new global clinical trial opportunities in the Asia/Pacific region.



CARL A. SPALDING
President and Chief Operating Officer

OPERATIONAL HIGHLIGHTS

On the operational front, we have continued to have a keen focus on quality. PAREXEL's commitment to quality includes continuously improving our systems, processes, workflows, standards, products, and communications. We understand that optimal performance, quality, depth and breadth of expertise and continuous innovation are key factors in winning new business and getting the opportunity to work on additional projects for existing customers.

These operational improvements yield a positive impact, not only on PAREXEL's financial performance, but also on our competitiveness and our ability to respond to the evolving needs of our clients and the marketplace.

Over the past fiscal year, we have observed several positive trends. For example, our employee turnover rate is at an historically low level, continuing the downward trend begun in Fiscal Year 2002. Thus, PAREXEL clients are better assured that they will experience minimal turnover of project staff. From a productivity standpoint, annualized revenue per full-time equivalent employee (FTE) increased 8% on a year-over-year basis, and approximately 18% over the past two years. Our employee development programs reflect the balance required to ensure retention of skills and provide an inflow of new knowledge and fresh perspective. We consider our Company to be an ideal environment in which to build a fulfilling career. Our commitment to training and development of our employees will continue to be a top priority in Fiscal Year 2004 and beyond.

I have been pleased with the improvements we have made in operating performance, control of SG&A, and profitability. In conjunction with our focus on margin improvement, we are also turning our attention to top line growth and increasing our share of the market. Generating top line growth while maintaining our intense focus on operating margin improvements should enable us to leverage our earnings potential.

KEY GROWTH AREAS

Driven by the evolving needs of our clients, PAREXEL continues to provide expertise and innovation most notably in the following four key growth areas:

Peri-Approval/Phase IV Services. Diminished periods of exclusivity and patent protection, combined with increased regulatory requirements for long-term safety data on bio/pharmaceutical products, has contributed to an increase in the overall number of peri-approval studies conducted. Clients seek to maximize market penetration, extend product lifecycles, expand prescribing communities, and increase the profitability of their existing product portfolios. PAREXEL supports these efforts through our PACE™ (Peri-Approval Clinical Excellence) team, providing the unique combination of scientific insight and clinical research expertise needed for successful Phase IIIb and IV studies and effective global Expanded Access Programs (EAP). Our global presence enables us to assist in the localization and customization of study design and allows us to rapidly assemble highly qualified project teams. Service customization for client-specific study requirements can include, for example, incorporating CRS project management expertise with the trial marketing and patient recruitment/education expertise of MMS and Perceptive's information tracking capabilities for studies involving large, diverse patient populations.

Medical Marketing Services. In recent years, medical marketing has taken on a larger role in building brand awareness and more quickly achieving peak sales in the bio/pharmaceutical business. PAREXEL's Medical Marketing Services organization has developed a unique competency in this area, combining strong marketing communication skills and clinical/medical/scientific knowledge

to deliver effective patient recruitment, physician education, strategic marketing decision-making, reimbursement programs, and managed care provider communications. The October 2002 acquisition of Pracon, a division of Excerpta Medica, Inc., broadened our expertise and enhanced our resources, particularly in the area of reimbursement assistance and medical communications, making us better equipped to help clients develop customized solutions for positioning and promoting their products. Additionally, we are strengthening our presence in the US, the largest potential market for our medical marketing services.

Clinical Pharmacology. Having distinguished itself as a service provider with international clinical pharmacology expertise, PAREXEL added to its capabilities in Fiscal Year 2003 with the expansion of our Clinical Pharmacology Research Units in Baltimore, Maryland and Northwick Park, United Kingdom. At the Baltimore facility, we more than doubled our capacity to support a full range of clinical pharmacology services, particularly for clients who need us to perform demanding studies involving complex procedures and monitoring techniques. With access to patient populations in the northern and southern hemispheres, PAREXEL's network of clinics established integrated quality management systems to assess, further improve and maintain the high standards that clients have come to expect.

Advanced Information Technology. We believe that Perceptive Informatics has emerged as a clinical research leader in management-related information technology – technologies that support various aspects of drug development and commercialization. That position was enhanced in Fiscal Year 2003 with the acquisitions of FW Pharma Systems, Ltd. and Invantage. FW Pharma developed IMPACT, a leading enterprise-wide clinical trial management system [CTMS], and INITIATOR, Phase I trial management software. These products, when combined with Perceptive Informatics' portfolio of innovative technologies, give us the ability to improve global clinical trial management on an enterprise-wide basis. Furthermore, the acquisition of Invantage enabled us to extend the capabilities of Perceptive Portal™ to include client proprietary investigator databases, thereby helping sponsors to more efficiently select study sites and accelerate other clinical trial start-up activities.

We believe the Perceptive portfolio of products provides the Company with multiple inherent growth opportunities. The business has excellent momentum given that Perceptive's backlog doubled during the course of Fiscal Year 2003.

GOALS FOR FISCAL YEAR 2004

As we look ahead to Fiscal Year 2004, we are excited about PAREXEL's prospects. In this regard, there are a number of indicators that outsourcing levels are healthy and growing. Last year, for example, the value of clinical research projects on which PAREXEL was invited to bid grew approximately 15% from Fiscal Year 2002 to 2003. Most importantly, many of our strongest client relationships are with

pharmaceutical companies that have robust pipelines including a large number of chemical entities that are advantageously positioned in their development lifecycle, from PAREXEL's point of view.

Margin improvement continues to be a key goal and we are pleased with the progress that was made over the past year. To help achieve our goal of reaching a 10% operating margin level by the end of Fiscal Year 2005, we are focusing on a number of factors including strong top line growth to better leverage our infrastructure.

Our key focus for the year ahead will include:


- Generating sufficient new business to continue to drive double-digit revenue growth
- Continuing to improve productivity and quality
- Crossing the break-even line into profitability for Perceptive Informatics
- Enhancing cross-Strategic Business Unit collaboration to allow us to customize our services to the evolving needs of our clients

Of course, my greatest source of pride and confidence is the people of PAREXEL. Whenever I meet clients, they invariably tell me how impressed they are with the quality, intelligence, and commitment of our people. Whether consulting with the former FDA officials in PCG, the bioanalytics experts in Clinical Pharmacology, the biostatisticians in Clinical Research, the MMS reimbursement analysts, the radiologists in medical imaging, the web portal developers from Perceptive, or any other member of the PAREXEL team, our clients know they are working with some of the most capable people in the industry. The expertise, insight, and counsel provided by our people are the greatest values that clients receive from working with PAREXEL. We will continue our commitment to training and development of our employees in Fiscal Year 2004.

CLOSING THOUGHTS

In the wake of recent corporate accounting scandals, an annual report would be incomplete without a note about corporate governance. Since we founded PAREXEL in 1983, we have steadfastly adhered to promoting integrity and maintaining the highest standards of business ethics and accounting practices that reflect the true financial picture of the Company. PAREXEL is equally committed to complying with applicable government mandates regarding corporate governance, including the Sarbanes-Oxley Act of 2002.


Finally, I'd like to thank you, our shareholders, for your continued support as we strive to increase the value of your investment in PAREXEL.



Josef H. von Rickenbach

Chairman of the Board and Chief Executive Officer

BIO/PHARMACEUTICAL
OUTSOURCING SERVICES COMPANY



"Bio/Pharmaceutical Services Company." For over two decades, PAREXEL has expanded the meaning of this term to the point where it now encompasses a breadth of service and product offerings, a level of expertise, a depth of commitment, and a degree of partnership and customer advocacy not envisioned by those who first coined it.

To our pharmaceutical, biotechnology and medical device clients, PAREXEL is many things. We are the regulatory professional who understands both the requirements and guidelines of working with government agencies worldwide; the innovator looking for ways to apply emerging technologies, processes, and methodologies to bring increased efficiency, speed, and quality to the development process; the dedicated project team who diligently oversees the end-to-end management and execution of clinical research studies, data management and analysis, and documentation; the creative director who knows how to craft communications to reach and educate prospective clinical trial patients and physicians; the bioanalytics expert with the ability to precisely measure even a trace amount of a compound in the bloodstream; and the medical technician who can accurately and consistently interpret medical images.

Above all, **PAREXEL is the company that clients can trust. We deliver reliable results. We provide expert insight and advice. We add value at every step of the drug development and commercialization process.** In doing so, we help our clients bring breakthrough therapies to market faster.

PAREXEL is the company
clients can trust. We deliver
reliable results. We provide
expert insight and advice.
We add value at every step
of the drug development and
commercialization process.



FASTER, EFFICIENT PATIENT RECRUITMENT

In a development process that can take years of rigorous science, painstaking experimentation, and the creation of voluminous regulatory documentation, it may seem strange that **the greatest delay in bringing new therapies to market is straightforward: recruiting the proper number of qualified patients for a clinical trial.**

Clinical trials that fail to meet patient enrollment deadlines are often the result of a lack of foresight into the challenges that may affect patient identification, referral, and recruitment. Out of a group of 200 seemingly healthy volunteers for a Phase I clinical trial, for example, perhaps only 10 fulfill the criteria required to be deemed truly "healthy." Furthermore, among certain target patient populations, there is often considerable competition from other clinical trials. Under-recruitment can cause delays – and lengthy delays can cost trial sponsors additional drug development time and loss of potential revenue.

PAREXEL can make the patient recruitment process fast, efficient, and productive through a combination of expert consultation and analysis, global resources, medical marketing skills, technology, and clinical expertise – all customized to each client's specific requirements.

Before recruitment even begins, we help clients develop detailed plans to avoid the pitfalls that can delay or compromise results. By enabling clients to conduct clinical studies on six continents and both hemispheres, we provide direct access to the largest and most diverse range of patient populations possible. PAREXEL has expertise in applying sophisticated and innovative communications directed to potential participants and medical professionals to aid the recruitment process – to reach the target patient populations and also to help potential participants make informed decisions regarding their participation.

PAREXEL brings new efficiencies to the enrollment process. When investigators respond via telephone, our Interactive Voice Response System (IVRS) enables our clients to screen and randomize patients to achieve balance among treatment arms and to support complex trial designs. We provide near real-time status on enrollment progress to enable quicker adjustment of recruitment plans when needed. We also provide complete inventory management of drug supply. Careful inventory management avoids costly waste of medication, enabling timely planning, and maximizing use of the existing trial drug supply.

PAREXEL has also developed proficiencies in supporting the special patient recruitment needs of Phase IV trials. Our Peri-Approval Clinical Excellence (PACE™) team helps our clients to recruit the high-risk patient populations who would benefit from early access to medically significant new therapies prior to registration for a particular indication. Examples include a 500-patient sepsis program at 80 sites in Europe and a 5,000-patient oncology program with 900 sites participating throughout the world.

From Asia to South America. From Phase I through Phase IV. From trial awareness campaigns to physician education. From referral programs to web-based portals. PAREXEL has made a science out of recruiting the patients our clients need to develop promising new medical therapies.



"Retrospective analysis, brought down to the site and country level, improves the predictability of enrollment, guides country allocation, and provides the foundation for realistic project timelines."

JIM KREMIDAS,
Global Enrollment Optimization and Innovation
Purdue and Company

The greatest delay in bringing
new therapies to market
straightforward: recruiting
the proper number of qualified
patients for a clinical trial.



BETTER DECISION-MAKING, EARLIER INTERVENTION

"Knowledge is power," declares the old maxim. And in bio/pharmaceutical development, early knowledge is even more powerful. **The sooner a development team can obtain solid, reliable data about the safety or efficacy of a new compound or device, the sooner the team can make informed decisions about its future.** These decisions are the kind that can save millions of dollars in drug development costs and months of testing and regulatory review.

PAREXEL offers its clients that power in a variety of ways – through advanced technologies, regulatory-compliant methodologies and processes, expert consulting, and market analysis and intelligence. Our Perceptive Informatics subsidiary conducts novel work using advanced diagnostic imaging tools to produce surrogate endpoints in clinical trials and provide an early start on the path to approval. That means the study sponsor can obtain early visual proof of the efficacy of certain drugs – for example, the degree to which an angiogenesis inhibitor cuts off the blood supply to a cancerous tumor – long before it would otherwise be possible. Our studies have included more than 150,000 imaging time-points from 40,000 patients located in 35 countries.

Following the recent acquisition of FW Pharma, Perceptive Informatics is now making critical trial data more accessible – and useful – to clients through its IMPACT clinical trial management software. IMPACT is a clinical trials management systems market leader, and is currently used by over half of the top 20 pharmaceutical companies based upon 2002 revenue, helping clients plan and monitor the progress of trials, track supplies and costs, and enter monitoring data remotely. By delivering data to clients in real time – instead of through already outdated reports – IMPACT enables decision-makers to identify and act on trends more quickly.

We offer our experience and expertise in a wide range of decision-making support techniques. PAREXEL Medical Marketing Services (MMS) employs decision conferencing, scenario planning, and portfolio and resource allocation modeling to help clients reach earlier "go/no go" decisions. Recent MMS client projects include the design and implementation of a portfolio prioritization process, as well as the coordination of scenario planning workshops in a variety of therapeutic areas.

But improving the speed of decision-making requires more than just the ability to weed out unpromising therapies earlier in the development process. If bio/pharmaceutical companies are unable to efficiently navigate the regulatory compliance and approval process, they face costly delays that can severely affect their stock prices, jeopardize funding, and permanently close windows of opportunity.

That's where the PAREXEL Consulting Group comes in. We have helped some of the best-known names in the Fortune 500 to develop and implement compliance strategies that give clients a competitive edge. With a team that includes former regulatory officials and leading industry experts, we offer high levels of insight into regulations and regulatory trends. Our combination of global capabilities and in-depth regional knowledge enables us to monitor consistency while also maintaining the flexibility to address local differences with proven services.


Reporting is another area where prompt and early action can pay big dividends in aiding earlier decision-making. By actively monitoring, collecting, reporting, and analyzing information on products as they move through the product lifecycle, and identifying adverse drug reactions or other safety-related events, our pharmacovigilance experts can help clients avoid costly missteps that can threaten both product revenues and reputations.

We also offer performance management tools that encourage accountability, better decision-making, and early intervention to help resolve issues before they become critical. For example, PAREXEL's Barnett International division worked with a client to design and implement metrics for clinical trial management. These "real time" metrics tools enabled clinical trial managers to pinpoint delays in study activity, plan resource needs, and re-allocate staff to meet changing demands. Ultimately, the client's clinical team credited PAREXEL's metrics support with enabling them to meet trial target dates in record time.

Our experience enables us to identify new opportunities to improve the drug development and commercialization process – and our commitment to our clients fuels the innovative solutions we deliver. With PAREXEL, knowledge truly is power – and it's getting more powerful all the time.

CT image of the liver shows a large metastatic lesion in the left lobe of the liver. Electronic calipers have been placed to capture the longest dimension (1.1). There is also a small metastatic lesion in the posterior aspect of the right lobe of the liver.

Image courtesy of Theracis International, Inc.




The sooner a development team can obtain solid, reliable data about the safety or efficacy of a new compound or device, the sooner the team can make informed decisions about its future.

"PAREXEL strives to provide a portfolio of products and services designed to individually and collectively improve the drug development process from early research to product launch and beyond. Our goal is to help reduce time-to-market and maximize our client's return on investment."

CARL A. SPALDING,
President and Chief Operating Officer
PAREXEL International Corporation



BIOTECH AND SMALL PHARMACEUTICAL CLIENT SERVICE AND SUPPORT



With the advances in biologic science driven by genomics and *bio-informatics*, a new and different breed of bio/pharmaceutical enterprise has emerged. Numbering in the hundreds, these early-stage biotech and pharmaceutical companies are often fairly small research teams of only a few dozen people.

Due to funding constraints and a lack of in-house experience, many of these companies are electing to go the "virtual" route - outsourcing development functions so they can focus on their area of expertise - research. For an increasing number of them, PAREXEL has become an extension of their internal team. We're an essential partner, adding value and extending client reach by providing a broad set of services to bring these clients all the way from the scientific idea stage through to proof of concept, development, partnering, and commercialization.

Our services for biotech and small to mid-sized pharma companies span all phases of development as well as medical marketing services. We help our clients by designing and performing early-stage clinical tests. Identifying and initiating clinical sites. Providing expert medical monitoring. Delivering regulatory and quality systems advice to ensure that manufacturing is GMP-compliant. Developing strategic drug development plans, portfolio prioritization, and market assessment for new compounds and leads. Acting as the key liaison between clients and regulators. Providing customized training and consulting assistance. **In short, we supply the knowledge, advice, credibility, and resources required to turn scientific concepts and aspirations into commercially viable medical therapies.**

PAREXEL is also making an impact by advancing the body of knowledge behind bio/pharmaceutical product testing. Our Clinical Pharmacology International Network works with clients through all of the complex and necessary stages of testing - *identifying new scientific procedures for optimized studies that will better predict how compounds will perform in Phase II and Phase III*. Thus, we create the prerequisites for quickly gaining advanced knowledge of a compound's therapeutic potential and efficacy.

PAREXEL also helps growing biotech and pharmaceutical clients by applying advanced scientific investigative techniques to the drug development process. Working in collaboration with a leading university-based center, we offer Positron Emission Tomography (PET) neuroimaging and radiochemistry. PET serves an important role as a surrogate marker helping to determine rational drug dosing, biodistribution of drugs, therapeutic rationale for drug utilization, and the mechanism of drug action.

But PAREXEL's skill set doesn't end there. With drug development costs escalating, market exclusivity diminishing, and an ever increasing number of new compounds reaching the market each year, the margin for error in building brand awareness and reducing time to peak sales is razor thin. PAREXEL's Medical Marketing Services (MMS) begins working with clients very early on, following proof of concept, to create pre-launch positioning and market development, and later, product awareness and key messaging and customized internal and external communications strategies and plans. These services are designed to provide cost-effective strategies that can help build momentum early in the product development process and carry that momentum through to product launch and beyond. We have worked with 8 of the 10 leading bio/pharmaceutical companies based upon 2002 R&D spending, and over the years have participated in over 20 successful product launches for 18 clients.

Working with PAREXEL, clients gain access to a level of biologics expertise and drug development and commercialization know-how that would be difficult, time-consuming, and expensive for them to develop on their own. Clients receive the benefit of experienced advice from seasoned, senior-level experts equal to those at larger pharmaceutical companies. PAREXEL also provides access to global markets through our locally-based professionals in many regions of the world. We support clients with fully staffed offices in the major biotech "hubs." And our clients have experienced a level of local attention and trust from regulatory agencies that they may not have received without a proven partner like PAREXEL at their side.

Take LG Life Sciences Ltd. (LGLS), for example. The South Korean drug developer and its partner, GeneSoft Pharmaceuticals, Inc., turned to PAREXEL for assistance after their Factive® antibiotic ran into a regulatory roadblock. Our consultants prepared a regulatory strategy for Factive®, analyzed and reworked the submission materials, and assisted in the presentation to the FDA, where it quickly won approval – the first Korean drug to do so.


With PAREXEL's expert resources behind them, emerging biotech and small to mid-sized pharmaceutical companies have the advantage they need to compete successfully in the global marketplace.

In short, we supply the knowledge, advice, credibility, and resources required to turn scientific concepts and aspirations into commercially viable medical therapies.

"PAREXEL provided the essential regulatory, clinical and clinical expertise that was needed to help GeneSoft Pharmaceuticals, Inc. succeed in making its case to the FDA that Factive® is an important new therapy for respiratory tract infections and multi-drug resistant *S. pneumoniae*. The combined efforts of PAREXEL, GeneSoft and academic expert consultants were key success factors in achieving this critically important milestone for our company – our first drug approval in the United States."

DAVID B. SINGER,
Chairman and Chief Executive Officer
GeneSoft Pharmaceuticals, Inc.





**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 10-K

**(X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended June 30, 2003

OR

**() TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission file number 0-27058

PAREXEL INTERNATIONAL CORPORATION

(Exact name of registrant as specified in its Charter)

MASSACHUSETTS

(State or other jurisdiction of
incorporation or organization)

04-2776269

(I.R.S. Employer
Identification Number)

195 WEST STREET

WALTHAM, MASSACHUSETTS

(Address of principal executive offices)

02451

(Zip Code)

Registrant's telephone number, including area code (781) 487-9900

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: NONE

SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:

Common Stock, \$.01 par value per share

(Title of class)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐.

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2). YES ☒ NO ☐.

State the aggregate market value of the voting stock held by nonaffiliates of the registrant:

The aggregate market value of Common Stock held by nonaffiliates as of December 31, 2002 was approximately \$162,119,567, based on the closing price of the registrant's Common Stock as reported on the NASDAQ National Market as of the last business day of the registrant's most recently completed second quarter.

Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date:

As of September 11, 2003, there were 25,863,684 shares of PAREXEL International Corporation Common Stock outstanding, excluding 930,829 shares in treasury.

DOCUMENTS INCORPORATED BY REFERENCE

Specified portions of the Registrant's Proxy Statement for the Annual Meeting of Stockholders to be held on November 11, 2003 are incorporated by reference into Item 5 of Part II and Part III of this report.

PAREXEL INTERNATIONAL CORPORATION

FORM 10-K ANNUAL REPORT

INDEX

PAGE

PART I

Item 1.	Business	3
Item 2.	Properties	20
Item 3.	Legal Proceedings	20
Item 4.	Submission of Matters to a Vote of Security Holders	20

PART II

Item 5.	Market for Registrant's Common Equity and Related Stockholder Matters	21
Item 6.	Selected Financial Data	21
Item 7.	Management's Discussion and Analysis of Financial Condition and Results of Operations	22
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	32
Item 8.	Financial Statements and Supplementary Data	34
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	57
Item 9A.	Controls and Procedures	57

PART III

Item 10.	Directors and Executive Officers of the Registrant	57
Item 11.	Executive Compensation	57
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	57
Item 13.	Certain Relationships and Related Transactions	57

PART IV

Item 14.	Principal Accountant Fees and Services	57
Item 15.	Exhibits, Financial Statement Schedule, and Reports on Form 8-K	58

SIGNATURES

59

PART I

The statements in this Annual Report on Form 10-K may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the adequacy of the Company's existing capital resources and future cash flows from operations, and statements regarding expected financial results, future growth and customer demand. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes”, “anticipates”, “plans”, “expects”, “intends”, “appears”, “will” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the Company's actual results, including the Company's actual operating performance, actual expense savings and other operating improvements resulting from restructurings, to differ materially from the results indicated by the forward-looking statements. These important factors are discussed in greater detail under “RISK FACTORS” below and elsewhere in this annual report.

The forward-looking statements included in this annual report represent the Company's estimates as of the date of this annual report. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this annual report.

ITEM 1. BUSINESS

GENERAL

PAREXEL International Corporation (“PAREXEL” or the “Company”) is a leading biopharmaceutical services company, providing a broad range of expertise in clinical research, medical marketing, consulting and informatics and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries. The Company's primary objective is to provide solutions for managing the biopharmaceutical product lifecycle with the goal of reducing the time, risk and cost associated with the development and commercialization of new therapies. Since its founding in 1983, PAREXEL has developed significant expertise in processes and technologies supporting this strategy. The Company's product and service offerings include: clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, performance improvement, industry training and publishing, web-based portal solutions, interactive voice response systems (“IVRS”), clinical trial management systems (“CTMS”), electronic data capture solutions, medical imaging services, and other drug development consulting services. The Company believes that its integrated services, depth of therapeutic area expertise, access to patients, and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Financial data on a business unit and geographic basis are included in Note 17 to the consolidated financial statements included in Item 8 of this annual report.

The Company's services complement the research and development (“R&D”) and marketing functions of pharmaceutical, biotechnology, and medical device companies. Through its clinical research and product launch services, PAREXEL seeks to help clients maximize the return on their significant investments in research and development by reducing the time, risk, and cost of clinical development and launch of new products. Outsourcing these types of services to PAREXEL provides clients with a variable cost alternative to the fixed costs associated with internal drug development. Clients no longer need to staff to peak periods and can benefit from PAREXEL's technical resource pool, broad therapeutic area expertise, global infrastructure designed to expedite parallel, multi-country clinical trials, and other advisory services focused on accelerating time-to-market. The Company's vision is to integrate and build critical mass in the complementary businesses of clinical research, medical marketing, drug development consulting, and information technology products and services. The Company's goal is to provide significant benefits to sponsor clients from this strategy, namely, a faster and less expensive development and launch process, as well as a clinical development strategy that optimally supports the marketing strategy for the new medical products.

The Company is one of the largest biopharmaceutical services company in the world, based upon annual service revenue. Headquartered near Boston, Massachusetts, the Company manages 57 locations and has approximately 5,095 employees throughout 36 countries around the world. The Company has operations in the major health care markets around the world, including the United States (“U.S.”), Canada, Japan, Germany, the United Kingdom (“U.K.”), France, Italy, Spain, Sweden, Australia, South Africa, Argentina, Brazil, Chile, Israel, Norway, Belgium, The Netherlands, Denmark, Finland and Central and Eastern Europe including Russia, Poland, the Czech Republic, Lithuania, Hungary, Romania, and the Ukraine. During fiscal year 2003, PAREXEL derived 48.2% of its service revenue from its international operations.

The Company was founded in 1983 as a regulatory affairs consulting firm and is a Massachusetts corporation. Josef H. von Rickenbach, Chairman of the Board and Chief Executive Officer of PAREXEL, was a co-founder. Since its inception, the Company has executed a focused growth strategy embracing internal expansion as well as strategic acquisitions to expand or enhance the Company's portfolio of services, geographic presence, therapeutic area knowledge, information technology capabilities, and client relationships. Acquisitions have been and may continue to be an important component of PAREXEL's growth strategy. The Company has completed nine acquisitions over the past five fiscal years.

DESCRIPTION OF BUSINESS

The Company provides a broad range of expertise in clinical research, medical marketing, consulting and informatics and advanced technology services to the worldwide pharmaceutical, biotechnology, and medical device industries. The Company is managed through four business segments: Clinical Research Services ("CRS"), the PAREXEL Consulting Group ("PCG"), Medical Marketing Services ("MMS"), and Perceptive Informatics, Inc. ("Perceptive"), a majority owned subsidiary of the Company. CRS constitutes the Company's core business and includes clinical trials management and biostatistics and data management, as well as related medical advisory and investigator site services. PCG provides technical expertise in such disciplines as clinical pharmacology, regulatory affairs, clinical and manufacturing compliance and validation services, industry training, publishing, and management consulting. PCG consultants identify options and propose solutions to address clients' product development, regulatory approval, and commercialization issues. MMS provides a full spectrum of brand positioning, market development, product development, targeted communications, continuing medical education, patient recruitment and strategic reimbursement services in support of product launch. Perceptive provides technology solutions to improve clients' product development and commercialization processes. Perceptive offers a portfolio of products and services that include web-based portals, interactive voice response systems, clinical trial management systems, electronic data capture solutions, investigator database, and medical imaging services. As of June 30, 2003, the Company owned an approximate 97.4% interest in Perceptive.

CLINICAL RESEARCH SERVICES

The Company's CRS business unit provides clinical trials management and biostatistical and data management services. Revenue from these services represented approximately \$312.8 million, or 61.1%, of the Company's consolidated service revenue for fiscal year 2003.

- ***Clinical Trials Management Services***

The CRS business unit offers complete services for the design, initiation and management of clinical trials programs, a critical element in obtaining regulatory approval for biopharmaceutical products. The Company has performed services in connection with trials in most therapeutic areas, including Cardiology, Oncology, Infectious Diseases, Neurology, Allergy/Immunology, Endocrinology/Metabolism, Gastroenterology, Obstetrics/Gynecology, Orthopedics, Pediatrics, Psychiatry, and Transplantation. PAREXEL's multi-disciplinary clinical trials group examines a product's existing preclinical and clinical data to design clinical trials to provide evidence of the product's safety and efficacy.

PAREXEL's CRS business unit can manage every aspect of clinical trials, including study and protocol design, Case Report Forms ("CRFs") design, site and investigator recruitment, patient enrollment, study monitoring and data collection, report writing and medical services. See "Government Regulations" for additional information. CRS's clinical trials projects involve Phases II, III, or IV clinical trials, which are generally larger, longer and more complex than Phase I trials.

Clinical trials are monitored for and with strict adherence to good clinical practice ("GCP"). The design of efficient CRFs, detailed operations manuals and site monitoring by PAREXEL's clinical research associates seek to ensure that clinical investigators and their staff follow the established protocols of the studies. The Company has adopted standard operating procedures ("SOPs"), which are intended to satisfy regulatory requirements and serve as a tool for controlling and enhancing the quality of PAREXEL's worldwide clinical services.

Clinical trials represent one of the most expensive and time-consuming parts of the overall biopharmaceutical development process. The information generated during these trials is critical for gaining marketing approval from the Food and Drug Administration ("FDA") and other regulatory agencies and market acceptance by clinicians and patients. The CRS business unit clinical trials management group assists clients with one or more of the following steps:

- **STUDY PROTOCOL DESIGN.** The protocol defines the medical issues the study seeks to examine and the statistical tests that will be conducted. Accordingly, the protocol defines the frequency and type of laboratory and clinical measures that are to be tracked and analyzed, the number of patients required to produce a statistically valid result, the period of time over which they must be tracked and the frequency and dosage of drug administration. The study's success depends on the protocol's ability to predict correctly the requirements of the regulatory authorities.

- **CRF DESIGN.** Once the study protocol has been finalized, the CRF must be developed. The CRF is the critical source document for collecting the necessary clinical data as dictated by the study protocol. The CRF may change at different stages of a trial. CRFs for one patient in a given study may consist of 100 or more pages.
- **SITE AND INVESTIGATOR RECRUITMENT.** The product under investigation is administered to patients by physicians, referred to as investigators, at hospitals, clinics, or other locations, referred to as sites. Medical devices are implemented or tested by investigators in similar settings. Potential investigators may be identified and solicited by the product sponsor. A significant portion of a trial's success depends on the successful identification and recruitment of experienced investigators with an adequate base of patients who satisfy the requirements of the study protocol. The Company has access to several thousand investigators who have conducted clinical trials for the Company. The Company also provides additional services at the clinical investigator site to assist physicians and expedite the clinical research process.
- **PATIENT ENROLLMENT.** The investigators, usually with the assistance of a clinical research organization ("CRO"), find and enroll patients suitable for the study. The speed with which trials can be completed is significantly affected by the rate at which patients are enrolled. Prospective patients are required to review information about the drug and its possible side effects, and sign an informed consent form to record their knowledge and acceptance of potential side effects. Patients also undergo a medical examination to determine whether they meet the requirements of the study protocol. Patients then receive the product and are examined by the investigator as specified by the study protocol. Investigators are responsible for administering the products to patients, as well as examining patients and conducting necessary tests.
- **STUDY MONITORING AND DATA COLLECTION.** As patients are examined and tests are conducted in accordance with the study protocol, data are recorded on CRFs. CRFs are collected from study sites by specially trained persons known as monitors. Monitors visit sites regularly to ensure that the CRFs are completed correctly and that all data specified in the protocol are collected. The monitors send completed CRFs to the study coordination site, where the CRFs are reviewed for consistency and accuracy before their data are entered into an electronic database. The Company offers several remote data entry ("RDE") technologies through Perceptive, which significantly enhance both the quality and timeliness of clinical data collection while achieving significant efficiency savings. The Company's study monitoring and data collection services comply with the FDA's adverse events reporting guidelines.
- **REPORT WRITING.** The statistical analysis findings for data collected during the trial together with other clinical data are included in a final report generated for inclusion in a regulatory document.
- **MEDICAL SERVICES.** Throughout the course of a development program, PAREXEL's physicians provide a wide range of medical research and consulting services to improve the speed and quality of clinical research, including medical supervision of clinical trials, compliance with medical standards and safety regulations, medical writing and strategy and product development.
- ***Biostatistical and Data Management Services***

PAREXEL's data management professionals provide a broad array of services to support the accurate collection, organization, validation and analysis of clinical data. For instance, they assist in the design of CRFs and investigator training manuals to ensure that data are collected in an organized and consistent format in compliance with the study protocol. Databases are designed according to the analytical specifications of the project and the particular needs of the client. Prior to data entry, PAREXEL personnel screen the data to detect errors, omissions and other deficiencies in completed CRFs. The use of RDE technologies to gather and report clinical data expedites data exchange while minimizing data collection errors as a result of more timely verification of data integrity. The CRS business unit provides clients with data abstraction, data review and coding, data entry, database verification and editing and resolution of data problems.

The CRS business unit has extensive experience throughout the world in the creation of scientific databases for all phases of the drug development process, including the creation of customized databases to meet client-specific formats, integrated databases to support new drug application submissions and databases in strict accordance with FDA, European and Asian specifications.

The CRS business unit biostatistics professionals assist clients with all phases of drug development, including biostatistical consulting, database design, data analysis and statistical reporting. These professionals develop and review protocols, design appropriate analysis plans and design report formats to address the objectives of the study protocol as well as the client's individual objectives. Working with programming staff, biostatisticians perform appropriate analyses and produce tables, graphs, listings and other applicable displays of results according to an analysis plan. Frequently, the CRS business unit biostatisticians represent clients during panel hearings at the FDA.

PAREXEL CONSULTING GROUP

The PCG business unit offers a number of consulting and advisory services in support of product development, regulatory and marketing processes. This group brings together experts from relevant disciplines and focuses on designing meaningful solutions and helping clients make the best business decisions with respect to their product lifecycle strategies. This group also serves as a valuable resource for the Company's internal operations. PCG includes four business units, KMI/PAREXEL, Worldwide Regulatory Affairs ("WRA"), Clinical Pharmacology and Barnett International ("Barnett"). Service revenue from the PCG business represented approximately \$100.6 million, or 19.7%, of consolidated service revenue for fiscal year 2003.

- ***KMI/PAREXEL***

KMI/PAREXEL offers manufacturing and information technology related services to the pharmaceutical, biopharmaceutical and medical device industries in the U.S and Europe. Employing an experienced team of former FDA investigators and experienced engineers, the Company uses its established methodologies and innovative information systems to assist clients in satisfying regulatory standards for manufacturing and quality systems processes throughout a product's lifecycle. KMI/PAREXEL has a staff of senior consultants with extensive experience and recognized expertise in good manufacturing practices ("GMP") and other FDA requirements. KMI/PAREXEL can evaluate clients' existing systems, help prepare for FDA inspections, conduct new drug application ("NDA") integrity audits, and develop regulatory correctional action plans.

KMI/PAREXEL also has the resources and experience to test processes, laboratory systems, automated unit operations, utilities, distributed control systems, and IS/IT management systems for manufacturing, laboratory and clinical and research applications for compliance with regulatory standards.

- ***Worldwide Regulatory Affairs***

Before a drug or medical device can be launched in a particular country, it must be approved by the regulatory agency having jurisdiction in that country. WRA provides comprehensive regulatory product registration services for pharmaceutical and biotechnology products and medical devices in major jurisdictions in North America, Europe, and Japan. These services include regulatory strategy formulation, regulatory document preparation and review, clinical quality assurance audits, regulatory training for client personnel, and expert liaison with the FDA and other regulatory agencies.

WRA works closely with clients to devise regulatory strategies and comprehensive registration programs. The Company's regulatory affairs experts review existing published literature, evaluate the scientific background of a product, assess the competitive and regulatory environment, identify deficiencies and define the steps necessary to obtain regulatory authority approvals in the most expeditious manner. Through these services, the Company helps its clients obtain regulatory approval for particular products or product lines in certain specific markets and participates fully in the product development process.

- ***Clinical Pharmacology***

Clinical pharmacology encompasses the early stages of clinical testing, when the product is first evaluated to prove safety and efficacy. These tests vary from "first in man" to "proof of concept studies" in Phases I and IIa of development. See "Governmental Regulations" for additional information. PCG's Clinical Pharmacology group provides drug development consulting, drug administration and monitoring, bioanalytical services, and patient recruitment. PAREXEL's international network of clinical pharmacology operations includes operations in Berlin (Germany), Baltimore, Maryland (U.S.), Bloemfontein (South Africa) and Harrow (U.K.), and bioanalytical laboratories in Bloemfontein and Poitiers (France). These laboratories perform bioanalytical analyses according to Good Laboratory Practices ("GLP") principles. With these locations, PCG's Clinical Pharmacology group offers clinical pharmacology services (including bioanalytical services) with a total of 245 dedicated beds (cooperating partners not included) on three continents. The network also cooperates with a pharmageriatrics center in Germany and a location, which specializes in renal and hepatic impairment, in Poland, Hungary, and the Czech Republic.

- ***Barnett International***

PCG's Barnett group offers a wide range of specialized clinical consulting, training, and publication services for the health care industry. Barnett provides management consulting in the clinical research area, offering a wide range of solutions that help pharmaceutical and biotechnology companies improve their own in-house clinical performance. These services include clinical process optimization, benchmarking and performance management, outsourcing management, design and development of SOPs, human performance assessment and management, technological analysis and implementation, and clinical training.

Barnett also offers conferences, seminars and educational materials, covering a multitude of topics in the clinical research field. The publications group produces several well recognized periodicals and special publications covering regulatory and drug development matters.

MEDICAL MARKETING SERVICES

Various pressures on the pharmaceutical industry have resulted in a greater focus on decreasing the time to peak sales in order to maximize revenue and profits over limited patent lives. MMS's strategy is to assist clients in achieving optimal market penetration for their products by providing customized, integrated and expert product pre-launch and launch services in the U.S., Europe, and internationally. Service revenue from the MMS business represented approximately \$73.8 million, or 14.4%, of consolidated service revenue in fiscal year 2003.

The Company's experience indicates that clients need assistance in creating awareness and understanding of their products in the marketplace and in addressing their products' rapid acceptance by opinion leaders, physicians, managed care organizations and patient groups leading to accelerated product acceptance and market penetration. MMS provides comprehensive, value-added pre and post-launch services, including market and opinion leader development, market preparation, and targeted communications support to clients. An integrated communications plan can detail external and internal strategies, including communications objectives, target audiences, communications priorities and timing, key messages, key meetings and events, and target publications and media. Other services include meetings and exhibitions planning, continuing medical education ("CME") programs to help keep medical professionals apprised of current medical developments, patient recruitment programs, strategies for medical manufacturers regarding reimbursement from insurance companies and managed care providers, telecommunications and call center support for patient assistance programs and Phase IV studies.

PERCEPTIVE INFORMATICS, INC.

Perceptive, a majority owned (approximately 97.4% as of June 30, 2003) subsidiary of PAREXEL, was formed by the Company in fiscal year 2000. Perceptive is a developing business that provides a variety of technology products and services designed to improve clients' product development and commercialization processes. The business currently offers a portfolio of information technology solutions that include web-based portals, interactive voice response systems, clinical trial management systems, electronic data capture solutions, medical imaging, and other related products and services that can be customized to clients' needs. Perceptive's web solutions support clinical trials management, communications, collaboration, and the viewing of metrics and clinical trial data. IVRS solutions support patient enrollment and randomization, management of study drug inventory and collection of diary information from clinical trial subjects. Perceptive's CTMS offerings include IMPACT and INITIATOR. IMPACT is an enterprise-wide clinical trial management system used to plan studies, track progress, support monitoring activities, track costs, and track clinical supplies. The system is used by approximately 30 pharmaceutical companies and by approximately 14,000 users worldwide. INITIATOR is a software package that assists in the management and conduct of trials by Phase I units. Perceptive's electronic data capture solutions have a potential to accelerate visibility of clinical data and decrease time to database lock. Perceptive's medical imaging services coordinate the use of a variety of medical imaging modalities (e.g., radiographs, ultrasound, computed tomography, magnetic resonance imaging, etc.) to evaluate product safety and efficacy. Perceptive performs ongoing market surveillance to identify and support new technologies that benefit clients as well as the Company's internal processes. Service revenue from the Perceptive business represented approximately \$24.8 million, or 4.8%, of consolidated service revenue for fiscal year 2003.

INFORMATION SYSTEMS

PAREXEL is committed to investing in information technology designed to help the Company provide high quality services in a cost-effective manner and to better manage its internal resources. The Company has built upon its information technology network by developing a number of proprietary information systems that address critical aspects of its business, such as project proposals/budget generation, time information management, revenue and resource forecasting, clinical data entry, data management, and project management.

The Company's internal Information Services group is responsible for technology planning and procurement, applications development, program management, operations, and management of the Company's worldwide computer network. The Company's information systems are designed to work in support of and reinforce the Company's SOPs. The Company's information technology system is open and flexible, allowing it to be adapted to the multiple needs of different clients and regulatory systems. This system also enables the Company to respond quickly to client inquiries regarding progress on projects and, in some cases, to gain direct access to client data on client systems.

SALES AND MARKETING

PAREXEL has personnel based in the Americas, Europe, and the Asia/Pacific region for the purpose of carrying out the Company's global business development activities. In addition to significant selling experience, most of these individuals have technical and/or scientific backgrounds. The Company's senior executives and project team leaders also participate in maintaining key client relationships and engaging in business development activities.

Each of the Company's business segments has an independent business development team that focuses on its particular market segment, and while all teams may work with the same client companies, the individuals they work with within the Company can vary. In many cases, however, the business segment selling teams work together in order to provide clients with the most appropriate service offering to meet their needs.

Each business development employee is generally responsible for a specific client segment or group of clients and for developing a strategy to maintain and strengthen an effective relationship with that client. Each individual is responsible for developing his or her client base, responding to client requests for information developing and defending proposals and making presentations to clients.

The business development group is supported by PAREXEL's global marketing organization, which is primarily based at the Company's headquarters in Waltham, Massachusetts. The Company's marketing activities consist primarily of brand management, collateral development, participation in industry conferences, advertising, public relations, e-marketing, publications, website development and maintenance, market information development and analysis, and strategic planning.

CLIENTS

The Company has in the past derived, and may in the future derive, a significant portion of its service revenue from a core group of major projects or clients. Concentrations of business in the biopharmaceutical services industry are not uncommon and the Company expects to experience such concentration in future years. In fiscal year 2003, the Company's five largest clients accounted for 33% of its consolidated service revenue. In fiscal year 2002, the Company's five largest clients accounted for 34% of its consolidated service revenue. In both fiscal years 2003 and 2002, one client, AstraZeneca PLC, accounted for 11% of consolidated service revenue. The loss of business from a significant client could materially and adversely affect the Company's service revenue and results of operations.

For fiscal year 2003, approximately 51.8% of the Company's service revenue was attributed to operations in the U.S. and approximately 48.2% of the Company's service revenue was attributed to operations outside the U.S. Financial data on a geographic basis are included in Note 17 to the consolidated financial statements in Item 8 of this annual report.

BACKLOG

Backlog represents anticipated service revenue from work not yet completed or performed under signed contracts, letters of intent, and certain verbal commitments. Once work commences, revenue is generally recognized over the life of the contract as services are provided. Backlog at June 30, 2003 was \$586.6 million, compared with \$540.0 million at June 30, 2002. The Company anticipates that approximately \$235.0 million of the backlog as of June 30, 2003 will be recognized as revenue after fiscal year 2004 concludes.

The Company believes that its backlog as of any date is not necessarily a meaningful predictor of future results. Projects under contracts included in backlog are subject to termination, revision, or delay. As detailed more fully in the "Risk Factors" section of this annual report, clients terminate, delay, or change the scope of projects for a variety of reasons including, among others, the failure of products being tested to satisfy safety requirements, unexpected or undesirable clinical results of the product, the clients' decision to forego a particular study, insufficient patient enrollment or investigator recruitment or production problems resulting in shortages of the drug. Generally, the Company's contracts can be terminated upon thirty to sixty days' notice by the client. The Company typically is entitled to receive certain fees (and, in some cases, a termination fee) for winding down a delayed or terminated project.

COMPETITION

The Company competes with other biopharmaceutical services companies and other organizations that provide one or more of the services currently being offered by the Company. Some of the larger biopharmaceutical services companies, such as Quintiles Transnational Corporation, Covance Inc., and Pharmaceutical Product Development Inc., offer services that compete directly with the Company's services at many levels.

PAREXEL believes that the synergies arising from integrating the products and services offered by its different business units, coupled with its global infrastructure (and related access to patients), technological expertise, and depth of experience differentiate it from its competitors. Although there are no guarantees that the Company will continue to do so, the Company believes that it competes favorably in all of its business areas. Increased competition could adversely affect operating results.

CRS

The clinical outsourcing services industry is very fragmented, with several hundred providers offering varying levels of service, skills and capabilities. The Company's CRS group primarily competes against in-house departments of pharmaceutical companies, other full service biopharmaceutical services companies, small specialty CROs, and to a lesser extent, universities, teaching hospitals, and other site organizations. The primary competitors for the CRS business include Quintiles Transnational Corporation, Covance Inc., Pharmaceutical Product Development Inc., Inveresk Research Group Inc., Kendle International Inc. and ICON PLC.

CROs generally compete on the basis of:

- previous experience with a client or in a specific therapeutic area;
- medical and scientific expertise in a specific therapeutic area;
- quality of services;
- breadth of services;
- the ability to organize and manage large-scale clinical trials on a global basis;
- the ability to manage large and complex medical databases;
- the ability to provide statistical and regulatory services;
- the ability to recruit investigators and patients;
- the ability to integrate information technology with systems to improve the efficiency of clinical research;
- an international presence with strategically located facilities;
- financial strength and stability; and
- price.

The Company believes CRS's key competitive strengths are its global footprint and the therapeutic knowledge and expertise of its employees.

PCG

PCG competes with a large and diverse group of specialty service providers, including major consulting firms with pharmaceutical industry practices, large and small biopharmaceutical services companies, smaller companies with a specific service focus, and individual consultants. The Company believes that no other company provides the unique combination of services that PCG provides. Furthermore, there is limited overlap of competitors from one service to the other because of the Company's varied service offerings. The competition in this segment is generally based on expertise, experience, reputation and price. The Company believes that PCG's key competitive strength is its breadth and depth of expertise in regulatory strategy, submissions and manufacturing compliance, and early stage drug development.

MMS

MMS competes with a large and fragmented group of companies including specialist medical marketing companies, large international advertising companies that offer medical education services, medical public relation firms, and small and large biopharmaceutical services companies that offer medical marketing and education services. The primary factors on which MMS competes include the ability to understand the commercial, medical/scientific, regulatory/reimbursement and communications issues involved in a successful pharmaceutical product launch; the ability to develop global marketing and communication strategies that accelerate product acceptance and market penetration; and the ability to translate those strategies into actionable activities and pricing. The Company believes that MMS's key competitive strengths are the innovative marketing services provided and the breadth of its varied service offerings.

PERCEPTIVE

The Perceptive business competes primarily with biopharmaceutical services companies, information technology companies and software companies. Companies in this segment compete based on the strength and usability of their technology offerings, their expertise and experience, and their understanding of the clinical development process. Perceptive's key competitive strength is its combination of technological expertise and knowledge of clinical development. The Company believes that its strategy of collaborating with other technology companies to implement certain tools, rather than developing its own, allows Perceptive to adapt to new technologies more quickly than many of its competitors. Perceptive's market position may be affected over time by competitors' efforts to develop and market new information technology products and services.

INTELLECTUAL PROPERTY

The Company's trademark "PAREXEL", is of material importance to the Company and it has registered this and other trademarks in the U.S. and many foreign countries. The duration of trademark registrations varies from country to country. However, trademarks are generally valid and may be renewed indefinitely as long as they are in use and/or their registrations are properly maintained, and they have not been found to have become generic.

EMPLOYEES

As of June 30, 2003, the Company had 5,095 employees. Approximately 42% of the employees are located in North America and 58% are located throughout Europe, Asia/Pacific and South America. The Company believes that its relations with its employees are good.

The success of the Company's business depends on its ability to attract and retain a qualified professional, scientific and technical staff. The level of competition among employers for skilled personnel, particularly those with Ph.D., M.D. or equivalent degrees, is high. The Company believes that its multinational presence, which allows for international transfers, is an advantage in attracting employees. In addition, the Company believes that the wide range of clinical trials in which it participates allows the Company to offer a broad experience to clinical researchers. There is no assurance that the Company will be able to attract and retain qualified staff in the future.

GOVERNMENT REGULATIONS

PAREXEL provides clinical trial and diverse consulting services for the drug, biologic and medical device industries. Lack of success in obtaining approval for the conduct of clinical trials can adversely affect the business. Lack of success in obtaining marketing approval or clearance for a product for which PAREXEL has provided clinical trial or other regulatory services can also adversely affect the business. However PAREXEL makes no guarantees to its clients with regard to successful outcomes of the regulatory process.

The clinical research services provided by PAREXEL in the U.S. are subject to ongoing FDA regulation. The Company is obligated to comply with FDA requirements governing activities such as obtaining patient informed consents, verifying qualifications of investigators, reporting patients' adverse reactions to products, and maintaining thorough and accurate records. The Company is also required to ensure that the computer systems it uses to process human data from clinical trials are validated in accordance with the electronic records regulations that apply to the pharmaceutical and CRO industries (21 CFR Part 11). The Company must maintain source documents for each study for specified periods, and such documents may be reviewed according to GCP standards by the study sponsor and the FDA during audits and inspections. Non-compliance with GCP can result in the disqualification of data collected during a clinical trial and in non-approval of a product application to the FDA.

The clinical investigation of new drugs, biologics and devices is highly regulated by government agencies. The standard for the conduct of clinical research and development studies comprises GCP, which stipulates procedures designed to ensure the quality and integrity of data obtained from clinical testing and to protect the rights and safety of clinical trial participants. The FDA and many other regulatory authorities require that study results submitted to such authorities be based on studies conducted in accordance with GCP. Specifically, in the European Union ("E.U.") clinical trials are subject to national regulation by each member state. Presently, the rules are not harmonized (see discussion of the International Conference on Harmonization ("ICH") below), but most member states require some form of notification or approval by government authorities, review and approval by independent ethics committees, and other measures to protect the interests of human subjects. As in the U.S., clinical trials in the E.U. are expected to be carried out in compliance with detailed requirements for GCP. The foreign regulatory approval process includes all of the risks and potential delays associated with the FDA approval process.

Because the FDA's regulatory requirements have served as the model for much of the regulation of new drug development worldwide, regulatory requirements similar to those of the FDA exist in the other countries in which the Company operates. The Company's regulatory capabilities include knowledge of the specific regulatory requirements in numerous countries. The Company has managed simultaneous regulatory submissions in more than one country for a number of drug sponsors for at least the past seven years. Beginning in 1991, the FDA and corresponding regulatory agencies of Canada, Japan and Western Europe commenced discussions to develop harmonized standards for preclinical and clinical studies and the format and content of applications for new drug approvals through a process known as ICH. Data from multinational studies adhering to GCP are now generally acceptable to the FDA, Canadian, Western European and Japanese regulators. The ICH process has sanctioned a single common format for drug and biologic marketing applications, known as the Common Technical Document ("CTD") in the U.S., Europe, Japan and Canada. On July 1, 2003 the CTD format became mandatory in Europe and Japan and highly recommended by the FDA in the U.S. and by the Canadian regulatory authorities. The Company has been developing the expertise to prepare CTDs for its clients in both paper and electronic form.

REGULATION OF DRUGS AND BIOLOGICS

Before a new drug or biologic may be approved and marketed, the drug or biologic must undergo extensive testing and regulatory review in order to determine that the drug or biologic is safe and effective. It is not possible to estimate the time in which preclinical, Phases I, II and III studies are completed with respect to a given product, if at all, although the time period may last many years. The stages of this development process are as follows:

Preclinical Research (approximately 1 to 3.5 years). In vitro ("test tube") and animal studies in accordance with GLP to establish the relative toxicity of the drug or biologic over a wide range of doses and to detect any potential to cause a variety of adverse conditions and diseases, including birth defects or cancer. If results warrant continuing development of the drug or biologic, the results of the studies are submitted to the FDA by the manufacturer as part of an Investigational New Drug Application ("IND"), which must be reviewed and cleared by the FDA before proposed clinical testing can begin. An IND must include, among other things, preclinical data, chemistry, manufacturing and control information, and an investigational plan, and must be activated by the FDA before such trials may begin. There can be no assurance that submission of an IND will result in the ability to commence clinical trials.

Clinical Trials (approximately 3.5 to 6 years)

- Phase I-Basic safety and pharmacology testing in approximately 20 to 80 human subjects, usually healthy volunteers, includes studies to determine metabolic and pharmacologic action of the product in humans, how the drug or biologic works, how it is affected by other drugs, how it is tolerated and absorbed, where it goes in the body, how long it remains active, and how it is broken down and eliminated from the body.
- Phase II-Basic efficacy (effectiveness) and dose-range testing, sometimes in 100 to 200 patients afflicted with a specific disease or condition for which the product is intended for use, to further test safety, begin evaluating effectiveness, optimize dose level, determine dose schedules, and determine routes of administration. If Phase II studies yield satisfactory results and no hold is placed on further studies by the FDA, Phase III studies can be commenced.
- Phase III-Larger scale, multi-center comparative clinical trials conducted with patients afflicted by a target disease in order to provide enough data for a valid statistical test of safety and effectiveness required by the FDA and others and to provide a basis for product labeling. When results from Phase II or Phase III show special promise in the treatment of a serious condition for which existing therapeutic options are nonexistent, limited or of minimal value, the FDA may allow the sponsor to make the new drug available to a larger number of patients through the regulated mechanism of a Treatment Investigational New Drug ("TIND"), which may span late Phase II, Phase III, and FDA review. Although TINDs may enroll and collect a substantial amount of data from tens of thousands of patients, they are not granted in all cases.

The FDA receives reports on the progress of each phase of clinical testing and may require the modification, suspension, or termination of clinical trials if, among other things, an unreasonable risk is presented to patients or if the design of the trial is insufficient to meet its stated objective.

NDA or Biologic License Application ("BLA") Preparation and Submission. Upon completion of Phase III trials, the sponsor assembles the statistically analyzed data from all phases of development, along with the chemistry and manufacturing and pre-clinical data and the proposed labeling, among other things, into a single large document, the NDA or BLA (in CTD format as of July 1, 2003), which today comprises, on average, roughly 100,000 pages.

FDA Review of NDA or BLA. Careful scrutiny of data from all phases of development (including a TIND) to confirm that the manufacturer has complied with regulations and that the drug or biologic is safe and effective for the specific use (or "indication") under study. The FDA may refuse to accept the NDA or BLA for filing and substantive review if certain administrative and content criteria are not satisfied and even after accepting the submission for review, the FDA may also require additional testing or information before approval of an NDA or BLA. The FDA must deny approval of an NDA or BLA if applicable regulatory requirements are not ultimately satisfied.

Post-Marketing Surveillance and Phase IV Studies. Federal regulation requires the sponsor to collect and periodically report to the FDA additional safety and efficacy data on the drug or biologic for as long as the manufacturer markets the product (post-marketing surveillance). If the product is marketed outside the U.S., these reports must include data from all countries in which the product is sold. Additional studies (Phase IV) may be undertaken after initial approval to find new uses for the product, to test new dosage formulations, or to confirm selected non-clinical benefits, e.g., increased cost-effectiveness or improved quality of life. Product approval may be withdrawn if compliance with regulatory standards is not maintained or if problems occur following initial marketing.

REGULATION OF MEDICAL DEVICES

Unless a medical device is exempted from pre-market submission and clearance, FDA approval or clearance of the device is required before the product may be marketed in the U.S. In order to obtain clearance for marketing, a manufacturer must demonstrate substantial equivalence to a similar legally marketed product by submitting a premarket notification, 510(k), to the agency. The FDA may require preclinical and clinical data to support a substantial equivalence determination, and there can be no assurance the FDA will find a device substantially equivalent. Clinical trials can take extended periods of time to complete. In addition, if the FDA requires an approved Investigational Device Exemption ("IDE") before clinical device trials may commence, there can be no guarantee that the agency will approve the IDE. An IDE approval process could also result in significant delay.

After submission of a premarket notification containing, among other things, any data collected, the FDA may find the device substantially equivalent and the device may be marketed. If the FDA finds that a device is not substantially equivalent, the manufacturer may request that the FDA make a risk-based classification to place the device in Class I or Class II. However, if a timely request for risk-based classification is not made, or if the FDA determines that a Class III designation is appropriate, an approved pre-market approval application ("PMA") will be required before the device may be marketed.

The PMA approval process is lengthy, expensive, and typically requires, among other things, extensive data from preclinical testing and a well-controlled clinical trial or trials that demonstrate a reasonable assurance of safety and effectiveness. There can be no assurance that review will result in timely or any PMA approval. There may also be significant conditions on approval, including limitations on labeling and advertising claims and the imposition of post-market testing, tracking, or surveillance requirements.

HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT OF 1996

Recent legislative changes protecting confidential medical information could impact the manner in which the Company conducts certain components of its business. On August 14, 2002, the Department of Health and Human Services issued final modifications to privacy regulations (the "Privacy Rule") under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"). These regulations impose new restrictions governing the disclosure of confidential medical information in the U.S. The Privacy Rule requires all companies subject to the rule to comply with its provisions on or before April 14, 2003.

The failure on the part of the Company, its clients and/or the physician investigators from whom the Company receives confidential medical information to comply with the Privacy Rule could result in the termination of ongoing research or the disqualification of data for submission to regulatory authorities. Additionally, the issuance of a notice of finding by a governmental authority against either the Company or its clients, based upon a material violation by the Company of any applicable regulation, could materially and adversely affect its business.

POTENTIAL LIABILITY AND INSURANCE

PAREXEL's clinical research services focuses on the testing of experimental drugs and devices on human volunteers pursuant to a study protocol. Clinical research involves a risk of liability for personal injury or death to patients due, among other reasons, to possible unforeseen adverse side effects or improper administration of the new drug. PAREXEL does not provide healthcare services directly to patients. Rather, PAREXEL physicians or physician investigators are responsible for administering drugs and evaluating patients. Many of these patients are already seriously ill and are at risk of further illness or death.

The Company believes that the risk of liability to patients in clinical trials is mitigated by various regulatory requirements, including the role of institutional review boards ("IRBs") and the need to obtain each patient's informed consent. The FDA requires each human clinical trial to be reviewed and approved by the IRB at each study site. An IRB is an independent committee that includes both medical and non-medical personnel and is obligated to protect the interests of patients enrolled in the trial. The IRB monitors the protocol and measures designed to protect patients, such as the requirement to obtain informed consent.

To reduce its potential liability, PAREXEL is generally successful in incorporating indemnity provisions into its contracts with clients and with investigators hired by the Company on behalf of its clients. These indemnities generally do not, however, protect PAREXEL against certain of its own actions, such as those involving negligence. Moreover, these indemnities are contractual arrangements that are subject to negotiation with individual clients, and the terms and scope of such indemnities can vary from client to client and from study to study. Finally, the financial performance of these indemnities is not secured, so that the Company bears the risk that an indemnifying party may not have the financial ability to fulfill its indemnification obligations. PAREXEL could be materially and adversely affected if it were required to pay damages or incur defense costs in connection with an uninsured claim that is outside the scope of an indemnity or where the indemnity, although applicable, is not performed in accordance with its terms.

The Company currently maintains an errors and omissions professional liability insurance policy, subject to deductibles and coverage limits. There can be no assurance that this insurance coverage will be adequate, or that insurance coverage will continue to be available on terms acceptable to the Company.

AVAILABLE INFORMATION

The Company's Internet website is <http://www.parexel.com>. The Company makes available through its website the Company's annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended. The Company makes these reports available free of charge through its website as soon as reasonably practicable after they have been electronically filed with, or furnished to, the Securities and Exchange Commission.

RISK FACTORS

In addition to other information in this report, the following risk factors should be considered carefully in evaluating the Company and its business, including forward-looking statements made in the section of this report entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and other forward-looking statements that the Company may make from time to time. If any of the following risks occur, the Company's business, financial condition, or results of operations could be materially adversely affected.

LOSS, MODIFICATION, OR DELAY OF LARGE OR MULTIPLE CONTRACTS MAY NEGATIVELY IMPACT THE COMPANY'S FINANCIAL PERFORMANCE

The Company's clients generally can terminate their contracts with the Company upon thirty to sixty days notice or can delay execution of services. The loss or delay of a large contract or the loss or delay of multiple contracts could adversely affect its operating results, possibly materially. The Company has in the past experienced contract cancellations, which have adversely affected its operating results. In both fiscal years 2003 and 2002, AstraZeneca accounted for 11% of the Company's consolidated service revenue. If AstraZeneca terminated all of its contracts with the Company, it would adversely affect the Company's operating results, possibly materially.

Clients terminate or delay their contracts for a variety of reasons, including, but not limited to:

- merger or potential merger related activities;
- failure of products being tested to satisfy safety requirements;
- failure of products being tested to prove effective;
- products having unexpected or undesired clinical results;
- client decisions to forego a particular study, perhaps for economic reasons;
- insufficient patient enrollment in a study;
- insufficient investigator recruitment;
- production problems which cause shortages of the product;
- product withdrawal following market launch; and
- manufacturing facility shut down.

In addition, the Company believes that companies regulated by the FDA may proceed with fewer clinical trials or conduct them without the assistance of biopharmaceutical services companies if they are trying to reduce costs as a result of budgetary limits or changing priorities. These factors may cause such companies to cancel contracts with biopharmaceutical services companies.

THE COMPANY FACES INTENSE COMPETITION IN MANY AREAS OF ITS BUSINESS; IF THE COMPANY DOES NOT COMPETE EFFECTIVELY, ITS BUSINESS WILL BE HARMED

The biopharmaceutical services industry is highly competitive, and the Company faces numerous competitors in many areas of its business. If the Company fails to compete effectively, the Company may lose clients, which would cause its business to suffer.

The Company primarily competes against in-house departments of pharmaceutical companies, other full service CROs, small specialty CROs, and to a lesser extent, universities, teaching hospitals, and other site organizations. Some of the larger CROs against which the Company competes include Quintiles Transnational Corporation, Covance, Inc. and Pharmaceutical Product Development Inc. In addition, PAREXEL's PCG and MMS businesses also compete with a large and fragmented group of specialty service providers, including advertising/promotional companies, major consulting firms with pharmaceutical industry groups and smaller companies with pharmaceutical industry focus. Perceptive, a majority owned subsidiary of the Company, competes primarily with CROs, information technology companies and other software companies. Some of these competitors, including the in-house departments of pharmaceutical companies, have greater capital, technical and other resources than the Company. In addition, those of the Company's competitors that are smaller specialized companies may compete effectively against the Company because of their concentrated size and focus.

THE FIXED PRICE NATURE OF THE COMPANY'S CONTRACTS COULD HURT ITS OPERATING RESULTS

Approximately 90% of the Company's contracts are at fixed prices. As a result, the Company bears the risk of cost overruns. If the Company fails to adequately price its contracts or if the Company experiences significant cost overruns, its gross margins on the contract would be reduced and the Company could lose money on contracts. In the past, the Company has had to commit unanticipated resources to complete projects, resulting in lower gross margins on those projects. The Company might experience similar situations in the future.

IF GOVERNMENTAL REGULATION OF THE DRUG, MEDICAL DEVICE AND BIOTECHNOLOGY INDUSTRY CHANGES, THE NEED FOR THE COMPANY'S SERVICES COULD DECREASE

Governmental regulation of the drug, medical device and biotechnology product development process is complicated, extensive, and demanding. A large part of the Company's business involves assisting pharmaceutical and biotechnology companies through the regulatory approval process. Changes in regulations, that, for example, streamline procedures or relax approval standards, could eliminate or reduce the need for the Company's services. If companies needed fewer of PAREXEL's services, the Company would have fewer business opportunities and its revenues would decrease, possibly materially.

In the U.S., the FDA and the Congress have attempted to streamline the regulatory process by providing for industry user fees that fund additional reviewer hires and better management of the regulatory review process. In Europe, governmental authorities have approved common standards for clinical testing of new drugs throughout the E.U. by adopting standards for GCP and by making the clinical trial application and approval process more uniform across member states starting in May 2004. In the past several years, Japan also has adopted GCP. The FDA has had GCP in place as a regulatory standard and requirement for new drug approval for many years. The U.S., Europe and Japan have also collaborated in the 11-year-long ICH, the purpose of which is to eliminate duplicative or conflicting regulations in the three regions. The ICH partners have agreed upon a common format for marketing applications that eliminates the need to tailor the format to each region. Such efforts and similar efforts in the future that streamline the regulatory process may reduce the demand for the Company's services.

For example, parts of PAREXEL's PCG business advise clients on how to satisfy regulatory standards for manufacturing processes and on other matters related to the enforcement of government regulations by the FDA and other regulatory bodies. Any reduction in levels of review of manufacturing processes or levels of regulatory enforcement, generally, would result in fewer business opportunities for the PCG business in this area.

IF THE COMPANY FAILS TO COMPLY WITH EXISTING REGULATIONS, ITS REPUTATION AND OPERATING RESULTS WOULD BE HARMED

The Company's business is subject to numerous governmental regulations, primarily relating to pharmaceutical product development and the conduct of clinical trials. If the Company fails to comply with these governmental regulations, it could result in the termination of the Company's ongoing research, development or sales and marketing projects, or the disqualification of data for submission to regulatory authorities. The Company also could be barred from providing clinical trial services in the future or be subjected to fines. Any of these consequences would harm the Company's reputation, its prospects for future work and its operating results. In addition, the Company may have to repeat research or redo trials. The Company may be contractually required to take such action at no further cost to the customer, but at substantial cost to the Company.

THE COMPANY MAY LOSE BUSINESS OPPORTUNITIES AS A RESULT OF HEALTH CARE REFORM AND THE EXPANSION OF MANAGED CARE ORGANIZATIONS

Numerous governments, including the U.S. government and governments outside of the U.S., have undertaken efforts to control growing health care costs through legislation, regulation and voluntary agreements with medical care providers and drug companies. If these efforts are successful, pharmaceutical, medical device and biotechnology companies may react by spending less on research and development. If this were to occur, the Company would have fewer business opportunities and its revenues could decrease, possibly materially.

For instance, in the past, the U.S. Congress has entertained several comprehensive health care reform proposals. The proposals were generally intended to expand health care coverage for the uninsured and reduce the growth of total health care expenditures. While the U.S. Congress has not yet adopted any comprehensive reform proposals, members of Congress may raise similar proposals in the future. The Company is unable to predict the likelihood that health care reform proposals will be enacted into law. In addition to health care reform proposals, the expansion of managed care organizations in the healthcare market may result in reduced spending on research and development. Managed care organizations' efforts to cut costs by limiting expenditures on pharmaceuticals and medical devices could result in pharmaceutical, biotechnology and medical device companies spending less on research and development. If this were to occur, the Company would have fewer business opportunities and its revenues could decrease, possibly materially.

NEW AND PROPOSED LAWS AND REGULATIONS REGARDING CONFIDENTIALITY OF PATIENT INFORMATION COULD RESULT IN INCREASED RISKS OF LIABILITY OR INCREASED COSTS TO THE COMPANY, OR COULD LIMIT THE COMPANY'S SERVICE OFFERINGS

The confidentiality and release of patient-specific information are subject to government regulation. Under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, the U.S. Department of Health and Human Services has issued regulations mandating heightened privacy and confidentiality protections. The federal government and state governments have proposed or adopted additional legislation governing the possession, use and dissemination of medical record information and other personal health information. Proposals being considered by state governments may contain privacy and security provisions that are more burdensome than the federal regulations. In order to comply with these regulations, the Company may need to implement new security measures, which may require the Company to make substantial expenditures or cause the Company to limit the products and services it offers. In addition, if the Company violates applicable laws, regulations or duties relating to the use, privacy or security of health information, it could be subject to civil or criminal liability.

IF THE COMPANY DOES NOT KEEP PACE WITH RAPID TECHNOLOGICAL CHANGES, ITS PRODUCTS AND SERVICES MAY BECOME LESS COMPETITIVE OR OBSOLETE, ESPECIALLY IN THE COMPANY'S PERCEPTIVE INFORMATICS BUSINESS

The biotechnology, pharmaceutical and medical device industries generally, and clinical research specifically, are subject to increasingly rapid technological changes. The Company's competitors or others might develop technologies, products or services that are more effective or commercially attractive than the Company's current or future technologies, products or services, or render its technologies, products or services less competitive or obsolete. If competitors introduce superior technologies, products or services and the Company cannot make enhancements to its technologies, products and services necessary to remain competitive, its competitive position will be harmed. If the Company is unable to compete successfully, it may lose customers or be unable to attract new customers, which could lead to a decrease in revenue.

BECAUSE THE COMPANY DEPENDS ON A SMALL NUMBER OF INDUSTRIES AND CLIENTS FOR ALL OF ITS BUSINESS, THE LOSS OF BUSINESS FROM A SIGNIFICANT CLIENT COULD HARM ITS BUSINESS, REVENUE, AND FINANCIAL CONDITION

The loss of, or a material reduction in the business of, a significant client could cause a substantial decrease in the Company's revenue and adversely affect its business and financial condition, possibly materially. In the fiscal year ended June 30, 2003, the Company's five largest clients accounted for 33% of its consolidated service revenue, and one client, AstraZeneca, accounted for 11% of consolidated service revenue. In the fiscal year ended June 30, 2002, the Company's five largest clients accounted for 34% of its consolidated service revenue, and one client, AstraZeneca, accounted for 11% of its consolidated service revenue. The Company expects that a small number of clients will continue to represent a significant part of its revenue. The Company's contracts with these clients generally can be terminated on short notice. The Company has in the past experienced contract cancellations with significant clients.

IF THE COMPANY'S PERCEPTIVE INFORMATICS BUSINESS IS UNABLE TO MAINTAIN CONTINUOUS, EFFECTIVE, RELIABLE AND SECURE OPERATION OF ITS COMPUTER HARDWARE, SOFTWARE AND INTERNET APPLICATIONS AND RELATED TOOLS AND FUNCTIONS, ITS BUSINESS WILL BE HARMED

The Company's Perceptive Informatics business involves collecting, managing, manipulating and analyzing large amounts of data, and communicating data via the Internet. Perceptive depends on the continuous, effective, reliable and secure operation of its computer hardware, software, networks, telecommunication networks, Internet servers and related infrastructure. If Perceptive's hardware or software malfunctions or access to Perceptive's data by internal research personnel or customers through the Internet is interrupted, its business could suffer. In addition, any sustained disruption in Internet access provided by third parties could adversely impact Perceptive's business.

Although Perceptive's computer and communications hardware is protected through physical and software safeguards, it is still vulnerable to fire, storm, flood, power loss, earthquakes, telecommunications failures, physical or software break-ins, and similar events. In addition, Perceptive's software products are complex and sophisticated, and could contain data, design or software errors that could be difficult to detect and correct. If Perceptive fails to maintain and further develop the necessary computer capacity and data to support its customers' needs, it could result in loss of or delay in revenue and market acceptance.

IF THE COMPANY IS UNABLE TO ATTRACT SUITABLE WILLING VOLUNTEERS FOR THE CLINICAL TRIALS OF ITS CLIENTS, ITS CLINICAL RESEARCH SERVICES BUSINESS MAY SUFFER

One of the factors on which the Company's CRS business competes is the ability to recruit patients for the clinical studies the Company is managing. These clinical trials rely upon the ready accessibility and willing participation of volunteer subjects. These subjects generally include volunteers from the communities in which the studies are conducted. Although to date these communities have provided a substantial pool of potential subjects for research studies, there may not be enough patients available with the traits necessary to conduct the studies. For example, if the Company manages a study for a treatment of a particular type of cancer, its ability to conduct the study may be limited by the number of patients that it can recruit that have that form of cancer. If multiple organizations are conducting similar studies and competing for patients, it could also make the Company's recruitment efforts more difficult. If the Company is unable to attract suitable and willing volunteers on a consistent basis, it would have an adverse effect on the trials being managed by its CRS business, which could have a material adverse effect on its CRS business.

IF THE COMPANY'S HIGHLY QUALIFIED MANAGEMENT AND TECHNICAL PERSONNEL LEFT, ITS BUSINESS WOULD BE HARMED

The Company relies on the expertise of its Chairman and Chief Executive Officer, Josef H. von Rickenbach. If Mr. von Rickenbach left, it would be difficult and expensive to find a qualified replacement with the level of specialized knowledge of the Company's products and services and the biopharmaceutical services industry. The Company is a party to an employment agreement with Mr. von Rickenbach, which may be terminated by the Company or Mr. von Rickenbach upon notice to the other party.

In addition, in order to compete effectively, the Company must attract and maintain qualified sales, professional, scientific and technical operating personnel. Competition for these skilled personnel, particularly those with a medical degree, a Ph.D. or equivalent degrees, is intense. The Company may not be successful in attracting or retaining key personnel.

THE COMPANY MAY HAVE SUBSTANTIAL EXPOSURE TO PAYMENT OF PERSONAL INJURY CLAIMS AND MAY NOT HAVE ADEQUATE INSURANCE TO COVER SUCH CLAIMS

The Company's Clinical Research Services business primarily involves the testing of experimental drugs or other regulated FDA products on consenting human volunteers pursuant to a study protocol. These services involve a risk of liability for personal injury or death to patients who participate in the study or who use a product approved by regulatory authorities after the clinical research has concluded, due to, among other reasons, possible unforeseen adverse side effects or improper administration of the new product by physicians. In some cases, these patients are already seriously ill and are at risk of further illness or death.

In order to mitigate the risk of liability, the Company seeks to include indemnity provisions in its Clinical Research Services contracts with clients. However, the Company is not able to include indemnity provisions in all of its contracts. The indemnity provisions the Company includes in these contracts would not cover its exposure if:

- the Company had to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnity; or
- a client failed to indemnify the Company in accordance with the terms of an indemnity agreement because it did not have
- the financial ability to fulfill its indemnification obligation or for any other reason.

The Company also carries product liability insurance to cover its risk of liability. However, the Company's insurance is subject to deductibles and coverage limits and may not be adequate to cover product liability claims. In addition, product liability coverage is expensive. In the future, the Company may not be able to maintain or obtain product liability insurance on reasonable terms, at a reasonable cost or in sufficient amounts to protect it against losses due to product liability claims.

THE COMPANY'S BUSINESS IS SUBJECT TO INTERNATIONAL ECONOMIC, POLITICAL AND OTHER RISKS THAT COULD NEGATIVELY AFFECT ITS RESULTS OF OPERATIONS OR FINANCIAL POSITION

The Company provides most of its services worldwide. The Company's service revenue from non-U.S. operations represented approximately 48.2% of total service revenue for the year ended June 30, 2003 and approximately 43.3% of total service revenue for the year ended June 30, 2002. In addition, the Company's service revenue from operations in the United Kingdom represented approximately 18.8% of total service revenue for the year ended June 30, 2003 and approximately 19.0% of total service revenue for the year ended June 30, 2002. The Company anticipates that service revenue from international operations may grow in the future. Accordingly, the Company's business is subject to risks associated with doing business internationally, including:

- changes in a specific country's or region's political or economic conditions, including Western Europe, in particular;
- potential negative consequences from changes in tax laws affecting its ability to repatriate profits;
- difficulty in staffing and managing widespread operations;
- unfavorable labor regulations applicable to its European operations;
- changes in foreign currency exchange rates; and
- longer payment cycles of foreign customers and difficulty of collecting receivables in foreign jurisdictions.

THE COMPANY'S OPERATING RESULTS HAVE FLUCTUATED BETWEEN QUARTERS AND YEARS AND MAY CONTINUE TO FLUCTUATE IN THE FUTURE, WHICH COULD AFFECT THE PRICE OF ITS COMMON STOCK

The Company's quarterly and annual operating results have varied and will continue to vary in the future as a result of a variety of factors. For example, the Company's income from operations was \$7.0 million for the quarter ended September 30, 2002, \$1.7 million for the quarter ended December 31, 2002, \$8.3 million for the quarter ended March 31, 2003, and \$3.6 million for the quarter ended June 30, 2003. Factors that cause these variations include:

- the level of new business authorizations in a particular quarter or year;
- the timing of the initiation, progress, or cancellation of significant project;
- exchange rate fluctuations between quarters or years;
- restructuring charges;
- the mix of services offered in a particular quarter or year;
- the timing of the opening of new offices;
- costs and the related financial impact of acquisitions;
- the timing of internal expansion;
- the timing and amount of costs associated with integrating acquisitions; and
- the timing and amount of startup costs incurred in connection with the introduction of new products, services or subsidiaries.

Many of these factors, such as the timing of cancellations of significant projects and exchange rate fluctuations between quarters or years, are beyond the Company's control.

Approximately 80-85% of the Company's operating costs are fixed in the short term. In particular, a significant portion of the Company's operating costs relate to personnel, which are estimated to have accounted for 70-75% of the Company's total operating costs in fiscal year 2003. As a result, the effect on the Company's revenues of the timing of the completion, delay or loss of contracts, or the progress of client projects, could cause its operating results to vary substantially between reporting periods.

If the Company's operating results do not match the expectations of securities analysts and investors as a result of these factors, the trading price of its common stock will likely decrease.

THE COMPANY'S REVENUE AND EARNINGS ARE EXPOSED TO EXCHANGE RATE FLUCTUATIONS

Approximately 48.2% of the Company's service revenue for the year ended June 30, 2003 and approximately 43.3% of the Company's service revenue for the year ended June 30, 2002 were from non-U.S. operations. The Company's financial statements are denominated in U.S. dollars; thus, factors associated with international operations, including changes in foreign currency exchange rates, could have a significant effect on its operating results. Exchange rate fluctuations between local currencies and the U.S. dollar create risk in several ways, including:

- **Foreign Currency Translation Risk.** The revenue and expenses of the Company's foreign operations are generally denominated in local currencies, primarily the British pound and the Euro, and then are translated into U.S. dollars for financial reporting purposes. For the year ended June 30, 2003, approximately 20.4% of total service revenue was denominated in British pounds and approximately 21.9% of total service revenue was denominated in Euros. For the year ended June 30, 2002, approximately 19.5% of total service revenue was denominated in British pounds and approximately 17.4% of total service revenue was denominated in Euros.
- **Foreign Currency Transaction Risk.** The Company's service contracts may be denominated in a currency other than the functional currency in which it performs the service related to such contracts.

Although the Company tries to limit these risks through exchange rate fluctuation provisions stated in its service contracts, or by hedging transaction risk with foreign currency exchange contracts, it may still experience fluctuations in financial results from its operations outside of the U.S., and may not be able to favorably reduce the currency transaction risk associated with its service contracts.

THE COMPANY'S BUSINESS HAS EXPERIENCED SUBSTANTIAL EXPANSION IN THE PAST AND SUCH EXPANSION AND ANY FUTURE EXPANSION COULD STRAIN ITS RESOURCES IF NOT PROPERLY MANAGED

The Company has expanded its business substantially in the past. Future rapid expansion could strain the Company's operational, human and financial resources. In order to manage expansion, the Company must:

- continue to improve operating, administrative and information systems;
- accurately predict future personnel and resource needs to meet client contract commitments;
- track the progress of ongoing client projects; and
- attract and retain qualified management, sales, professional, scientific and technical operating personnel.

If the Company does not take these actions and is not able to manage the expanded business, the expanded business may be less successful than anticipated, and the Company may be required to allocate additional resources to the expanded business, which it would have otherwise allocated to another part of its business.

The Company may face additional risks in expanding its foreign operations. Specifically, the Company may find it difficult to:

- assimilate differences in foreign business practices, exchange rates and regulatory requirements;
- operate amid political and economic instability;
- hire and retain qualified personnel; and
- overcome language, tariff and other barriers.

THE COMPANY MAY MAKE ACQUISITIONS IN THE FUTURE, WHICH MAY LEAD TO DISRUPTIONS TO ITS ONGOING BUSINESS

The Company has made a number of acquisitions and will continue to review new acquisition opportunities. If the Company is unable to successfully integrate an acquired company, the acquisition could lead to disruptions to the business. The success of an acquisition will depend upon, among other things, the Company's ability to:

- assimilate the operations and services or products of the acquired company;
- integrate acquired personnel;
- retain and motivate key employees;
- retain customers; and
- minimize the diversion of management's attention from other business concerns.

Acquisitions of foreign companies may also involve additional risks, including assimilating differences in foreign business practices and overcoming language and cultural barriers.

In the event that the operations of an acquired business do not meet the Company's performance expectations, the Company may have to restructure the acquired business or write-off the value of some or all of the assets of the acquired business.

THE COMPANY'S CORPORATE GOVERNANCE STRUCTURE, INCLUDING PROVISIONS OF ITS ARTICLES OF ORGANIZATION AND BY-LAWS AND ITS SHAREHOLDER RIGHTS PLAN, AND MASSACHUSETTS LAW MAY DELAY OR PREVENT A CHANGE IN CONTROL OR MANAGEMENT THAT STOCKHOLDERS MAY CONSIDER DESIRABLE

Provisions of the Company's articles of organization, by-laws and its shareholder rights plan, as well as provisions of Massachusetts law, may enable the Company's management to resist acquisition of the Company by a third party, or may discourage a third party from acquiring the Company. These provisions include the following:

- the Company has divided its board of directors into three classes that serve staggered three-year terms;
- the Company is subject to Section 50A of the Massachusetts Business Corporation Law which provides that directors may only be removed by stockholders for cause, vacancies in the Company's board of directors may only be filled by a vote of the Company's board of directors and the number of directors may be fixed only by the Company's board of directors;
- the Company is subject to Chapter 110F of the Massachusetts General Laws which limits its ability to engage in business combinations with certain interested stockholders;
- the Company's stockholders are limited in their ability to call or introduce proposals at stockholder meetings; and
- the Company's shareholder rights plan would cause a proposed acquirer of 20% or more of the Company's outstanding shares of common stock to suffer significant dilution.

These provisions could have the effect of delaying, deferring, or preventing a change in control of the Company or a change in the Company's management that stockholders may consider favorable or beneficial. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors and take other corporate actions. These provisions could also limit the price that investors might be willing to pay in the future for shares of the Company's stock. In addition, the Company's Board of Directors may issue preferred stock in the future without stockholder approval. If the Company's Board of Directors issues preferred stock, the holders of common stock would be subordinate to the rights of the holders of preferred stock. The Company's Board of Directors' ability to issue the preferred stock could make it more difficult for a third party to acquire, or discourage a third party from acquiring, a majority of the Company's stock.

THE COMPANY'S STOCK PRICE HAS BEEN AND MAY IN THE FUTURE BE VOLATILE, WHICH COULD LEAD TO LOSSES BY INVESTORS

The market price of the Company's common stock has fluctuated widely in the past and may continue to do so in the future. On August 15, 2003, the closing sale price of the Company's common stock on the NASDAQ National Market was \$16.46 per share. During the period from July 1, 2001 to June 30, 2003, the closing sale price of the Company's common stock ranged from a high of \$19.60 per share to a low of \$8.05 per share. Investors in the Company's common stock must be willing to bear the risk of such fluctuations in stock price and the risk that the value of an investment in the Company's stock could decline.

The Company's stock price can be affected by quarter-to-quarter variations in:

- operating results;
- earnings estimates by analysts;
- market conditions in the industry;
- prospects of health care reform;
- changes in government regulations; and
- general economic conditions.

In addition, the stock market has from time to time experienced significant price and volume fluctuations that are not related to the operating performance of particular companies. These market fluctuations may adversely affect the market price of the Company's common stock. Since the Company's common stock has traded in the past at a relatively high price-earnings multiple, due in part to analysts' expectations of earnings growth, the price of the stock could quickly and substantially decline as a result of even a relatively small shortfall in earnings from, or a change in, analysts' expectations.

ITEM 2. PROPERTIES

As of June 30, 2003, the Company occupied approximately 1,375,000 square feet of building space in 57 locations in 27 countries around the world. Except for the property in Poitiers, France, the Company does not own any properties but leases its building space under various leases that expire between 2003 and 2022.

The Company's headquarters occupy 212,000 square feet of leased space in Waltham, Massachusetts under a lease that expires in 2009 and the Company's CRS and PCG segment, along with General Administrative staffs occupy 87,000 square feet of leased space in Uxbridge, U.K. under a lease that expires in 2022. The Company's non-U.S. facilities account for approximately 660,000 square feet. In particular, the Company occupies approximately 215,000 square feet in various locations in the United Kingdom, 185,000 square feet in various locations in Germany and 75,000 square feet in various locations in France.

The following table indicates the approximate square footage of property attributable to each of the Company's operating segments:

	Total Sq. Ft.
CRS	618,750
PCG	247,500
MMS	151,250
Perceptive	68,750
General Administrative	288,750

See Note 14 to the consolidated financial statements included in Item 8 of this annual report for further information regarding the Company's lease obligations.

ITEM 3. LEGAL PROCEEDINGS

The Company periodically becomes involved in various claims and lawsuits that are incidental to its business. The Company believes, after consultation with counsel, that no matters currently pending would, in the event of an adverse outcome, have a material impact on its consolidated financial position, results of operations or liquidity.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to a vote of security holders during the fourth quarter of fiscal year 2003.

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

The Company's common stock is quoted on the NASDAQ National Market under the symbol "PRXL". The table below shows the high and low sales prices of the common stock for each quarter of the fiscal years ended June 30, 2003 and 2002, respectively, on the NASDAQ National Market. The quotations in the table below reflect inter-dealer prices without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

	<u>2003</u>		<u>2002</u>	
	<u>High</u>	<u>Low</u>	<u>High</u>	<u>Low</u>
First Quarter	\$14.45	\$8.47	\$19.74	\$10.46
Second Quarter	\$13.53	\$8.05	\$16.20	\$10.14
Third Quarter	\$14.87	\$10.17	\$17.40	\$13.00
Fourth Quarter	\$14.75	\$11.80	\$16.08	\$11.95

As of September 8, 2003, there were approximately 94 stockholders of record. The number does not include shareholders for which shares were held in a "nominee" or "street" name.

The Company has never declared or paid any cash dividends on its Common Stock and does not anticipate paying any cash dividend in the foreseeable future. The Company intends to retain future earnings for the development and expansion of its business.

Information with respect to securities authorized for issuance under the Company's equity compensation plans may be found under the caption "Equity Compensation Plan Information" in the Proxy Statement for the Company's 2003 Annual Meeting of Stockholders. Such information is incorporated herein by reference.

ITEM 6. SELECTED FINANCIAL DATA

(in thousands, except per share data and number of employees)

	<u>2003</u>	<u>2002</u>	<u>2001</u>	<u>2000</u>	<u>1999</u>
<u>OPERATIONS</u>					
Service revenue	\$512,054	\$444,318	\$387,560	\$378,150	\$348,486
Income (loss) from operations	20,605(1)	20,493	(6,860) (2)	2,983 (3)	20,564(4)
Net income (loss)	10,662	13,235	(825)	4,388	15,622
Basic earnings (loss) per share	\$0.42	\$0.53	\$(0.03)	\$0.18	\$0.63
Diluted earnings (loss) per share	\$0.42	\$0.52	\$(0.03)	\$0.17	\$0.62
<u>FINANCIAL POSITION</u>					
Cash, cash equivalents and marketable securities	\$82,724	\$66,109	\$60,949	\$90,530	\$89,957
Working capital	134,346	138,020	123,488	123,680	132,757
Total assets	464,237	407,161	361,534	351,940	333,565
Long-term debt	644	432	12	104	79
Stockholders' equity	\$227,100	\$200,077	\$177,822	\$186,133	\$192,032
<u>OTHER DATA</u>					
Purchase of property and equipment	\$29,985	\$23,808	\$18,145	\$19,089	\$18,910
Depreciation and amortization	\$20,656	\$17,893	\$21,453	\$21,934	\$17,932
Number of employees	5,095	4,930	4,640	4,200	4,198
Weighted average shares used in computing:					
Basic earnings (loss) per share	25,371	24,928	24,637	24,981	24,848
Diluted earnings (loss) per share	25,683	25,582	24,637	25,140	25,128

- (1) Income from operations for the year ended June 30, 2003 includes \$9.4 million in facilities-related restructuring charges as a result of changes in prior assumptions regarding certain leased facilities, which were previously abandoned as part of the Company's June 2001 restructuring. The changes in assumptions were caused by the deterioration in the commercial real estate market. See Note 7 to the consolidated financial statements included in Item 8 of this annual report for further detail.
- (2) Loss from operations for the year ended June 30, 2001, includes a restructuring benefit of \$0.7 million. This consisted of a \$1.5 million reduction in previously accrued restructuring charges due to changes in estimates related to the third quarter 2000 restructuring, offset by \$0.8 million for exiting a business location in the U.S. Also in the year ended June 30, 2001, the Company recorded restructuring charges of \$7.2 million. These charges included \$3.1 million of employee severance and related costs for eliminating approximately 125 managerial and staff positions worldwide (44% in the U.S. and 56% in Europe), \$3.9 million related to consolidation and abandonment of certain facilities (40% in the U.S. and 60% in Europe), and approximately \$0.2 million primarily related to miscellaneous costs associated with the Company's fourth quarter restructuring plan. Additionally, the Company recorded \$1.0 million in accelerated depreciation expense due to changes in the estimated useful lives of leasehold improvements in abandoned leased facilities, \$0.9 million of one-time asset write-offs, as well as \$0.6 million in expenses associated with discontinued services.
- (3) Income from operations for the year ended June 30, 2000 includes \$13.1 million related to restructuring and other charges recorded in the third quarter, consisting primarily of severance and lease termination costs and \$1.0 million related to accelerated depreciation expense due to changes in the estimated useful lives of leasehold improvements on abandoned leased facilities.
- (4) Income from operations for the year ended June 30, 1999 includes \$4.7 million in nonrecurring charges including \$1.9 million in costs related to the terminated merger agreement with Covance Inc. and \$2.8 million in leasehold abandonment charges resulting primarily from the consolidation of certain facilities in North America and Europe.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

The Company is a leading biopharmaceutical services company, providing a broad range of expertise in clinical research, medical marketing, consulting and informatics and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries. The Company's primary objective is to provide solutions for managing the biopharmaceutical product lifecycle with the goal of reducing the time, risk and cost associated with the development and commercialization of new therapies. Since its founding in 1983, PAREXEL has developed significant expertise in processes and technologies supporting this strategy. The Company's product and service offerings include: clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, performance improvement, industry training and publishing, web-based portal solutions, interactive voice response systems, clinical trial management systems, electronic data capture solutions, medical imaging services, and other drug development consulting services. The Company believes that its integrated services, depth of therapeutic area expertise, access to patients, and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths.

The Company is managed through four business segments, namely, CRS, PCG, MMS and Perceptive. CRS constitutes the Company's core business and includes clinical trials management and biostatistics and data management, as well as related medical advisory and investigator site services. PCG provides technical expertise in such disciplines as clinical pharmacology, regulatory affairs, industry training, publishing, and management consulting. PCG consultants identify alternatives and propose solutions to address clients' product development, registration, and commercialization issues. MMS provides a full spectrum of market development, product development, and targeted communications services in support of product launch. Perceptive provides technology solutions to improve clients' product development and commercialization processes. Perceptive offers a portfolio of services that includes the design of web-based portals, IVRS, CTMS, electronic data capture solutions, and medical imaging. Perceptive is a majority-owned subsidiary of the Company. As of June 30, 2003, the Company owned an approximate 97.4% interest in Perceptive.

The Company conducts a significant portion of its operations in foreign countries. Approximately 48.2% and 43.3% of the Company's service revenue for the fiscal years ended June 30, 2003 and 2002, respectively, were from non-U.S. operations. Because the Company's financial statements are denominated in U.S. dollars, changes in foreign currency exchange rates can have a significant effect on its operating results. For the fiscal year ended June 30, 2003, approximately 20.4% of total service revenue was denominated in British Pounds and approximately 21.9% of total service revenue was denominated in Euros. For the fiscal year ended June 30, 2002, approximately 19.5% of total service revenue was denominated in British Pounds and approximately 17.4% of total service revenue was denominated in Euros. As a result of the weakened U.S. dollar against the British Pound and the Euro in fiscal year 2003, the Company's revenues and the Company's costs increased in 2003 from the comparable 2002 periods due to these exchange rate fluctuations.

Approximately 90% of the Company's contracts are fixed price, with some variable components, and range in duration from a few months to several years. Cash flow from these contracts typically consists of a down payment required to be paid at the time of contract execution with the balance due in installments over the contract's duration, usually on a milestone achievement basis. Revenue from these contracts is generally recognized as work is performed. As a result, cash receipts do not necessarily correspond to costs incurred and revenue recognized on contracts.

Generally, the Company's clients can terminate their contracts with the Company upon thirty to sixty days' notice or can delay execution of services. Clients may terminate or delay contracts for a variety of reasons, including, among others: merger or potential merger related activities involving the client, the failure of products being tested to satisfy safety requirements or efficacy criteria, unexpected or undesired clinical results of the product, client cost reductions as a result of budgetary limits or changing priorities, the client's decision to forego a particular study, insufficient patient enrollment or investigator recruitment, or production problems resulting in shortages of the product.

CRITICAL ACCOUNTING POLICIES

The discussion and analysis of the Company's financial condition and results of operations are based on the Company's consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and other financial information. On an ongoing basis, the Company evaluates its estimates and judgments, including those related to revenue recognition. The Company bases its estimates on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

While the Company's significant accounting policies are more fully described in Note 2 to the consolidated financial statements included in Item 8 of this annual report, the Company believes that the following accounting policies are most critical to aid in fully understanding and evaluating its reported financial results.

Revenue

Service revenue on fixed-price contracts is recognized as services are performed. The Company measures progress for fixed-price contracts using the concept of proportional performance based upon a direct labor cost-to-cost methodology or by the unit based output method. These methods require the Company to estimate total expected revenue and total expected costs. Generally, the assigned financial manager or financial analyst reviews contract estimates on a monthly basis. Adjustments to contract estimates are made in the periods in which the facts that require the revisions become known. Historically, there have not been any significant variations between contract estimates and the actual costs incurred, which were not recovered from clients. In the event that future estimates are materially incorrect, they could materially impact the Company's consolidated results of operations or financial position.

Billed Accounts Receivable, Unbilled Accounts Receivable and Deferred Revenue

Billed accounts receivable represent amounts for which invoices have been sent to clients. Unbilled accounts receivable represent amounts recognized as revenue for which invoices have not yet been sent to clients. Deferred revenue represents amounts billed or payments received for which revenue has not yet been earned. The Company maintains an allowance for doubtful accounts based on historic collectability and specific identification of potential problem accounts. In the event the Company is unable to collect portions of its outstanding billed or unbilled receivables, there may be a material impact to the Company's consolidated results of operations and financial position.

Income Taxes

The Company's global provision for corporate income taxes is calculated using the tax accounting rules established by SFAS No. 109. Income tax expense is based on the distribution of profit before tax amongst the various taxing jurisdictions in which the Company operates, adjusted as required by the tax laws of each taxing jurisdiction. Changes in the distribution of profits and losses between taxing jurisdictions may have a significant impact on the Company's effective tax rate. The provision is a combination of current-year tax liability and future tax liability/benefit that results from differences between book and taxable income that will reverse in future periods. Deferred tax assets and liabilities for these future tax effects are established on the Company's balance sheet. A valuation allowance is established if it is more likely than not that future tax benefits will not be realized. Monthly interim tax provision calculations are prepared during the year. Differences between these interim estimates and the final results for the year could materially impact the Company's effective tax rate and its consolidated results of operations and financial position.

Employee Stock Compensation

The Company elected to follow Accounting Principal Board Opinion No. 25, "Accounting for Stock Options Issued to Employees" ("APB 25"), and related interpretations in accounting for the Company's employee stock options because the alternative fair value accounting provided for under SFAS No. 123, "Accounting for Stock-Based Compensation" ("SFAS 123"), requires use of option valuation models that were not developed for use in valuing employee stock options. Under APB 25, no compensation expense is recognized if the exercise price equals the market price of the underlying stock on the date of the grant. If PAREXEL accounted for stock options under SFAS 123, the Company would have recorded additional compensation expense for stock option grants to employees. If PAREXEL were unable to account for stock options under APB 25, the Company's financial results would be materially affected to the extent that additional compensation expense had to be recognized. The additional compensation expense could vary significantly from period to period based on several factors including the number of stock options granted and stock price and/or interest rate fluctuations.

Foreign Currencies

The Company derives a large portion of its service revenue from operations in foreign countries. The Company's financial statements are denominated in U.S. dollars. As a result, factors associated with international operations, including changes in foreign currency exchange rates, could significantly affect the Company's results of operations. Gains and losses on transactions denominated in currencies other than an entity's functional currency are reported in other income (expense). Adjustments from the translation of the subsidiary entities' foreign functional currencies to U.S. dollars are reported in accumulated other comprehensive income/(loss) within stockholder's equity.

Goodwill

Goodwill represents the excess of the cost of an acquired business over the fair value of the related net assets at the date of acquisition. Prior to the adoption of SFAS No. 142, "Goodwill and Other Intangible Assets", goodwill was amortized using the straight-line method over the expected useful life. Subsequent to the adoption of SFAS No. 142, goodwill is subject to annual impairment testing. The Company has assessed the impairment of goodwill under SFAS No. 142 in fiscal years 2003 and 2002. Based on this assessment, there was no impairment identified at June 30, 2003 and 2002. Any future impairment of goodwill could have a material impact to the Company's financial position or its results of operations.

RESULTS OF OPERATIONS

QUARTERLY OPERATING RESULTS (UNAUDITED)

The following is a summary of unaudited quarterly results of operations for the two years ended June 30, 2003 and 2002.

For the year ended June 30, 2003
(in thousands, except per share data)

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Total Year
Service revenue	\$119,353	\$122,348	\$132,263	\$138,090	\$512,054
Income from operations	7,003	1,733	8,281	3,588	20,605
Net income	3,263	142	4,375	2,882	10,662
Diluted earnings per share	\$0.13	\$0.01	\$0.17	\$0.11	\$0.42

For the year ended June 30, 2002
(in thousands, except per share data)

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Total Year
Service revenue	\$101,840	\$106,874	\$112,027	\$123,577	\$444,318
Income from operations	2,517	4,201	4,556	9,219	20,493
Net income	2,456	3,068	3,711	4,000	13,235
Diluted earnings per share	\$0.10	\$0.12	\$0.14	\$0.16	\$0.52

ACQUISITIONS AND IMPACT OF RESTRUCTURING AND OTHER CHARGES

On January 31, 2003, the Company acquired 100% of the outstanding stock of FWPS Group Limited (FW Pharma), a provider of software for clinical trial management systems in Birmingham, United Kingdom, for approximately \$11.9 million in the form of a combination of cash and shares of the Company's common stock. The Company originally issued an aggregate of 238,095 shares (valued at approximately \$3.0 million) of its common stock to stockholders of FWPS Group Limited in connection with the acquisition. Of these shares, 32,854 shares were surrendered back to the Company by FW Pharma stockholders pursuant to the purchase price adjustment provisions of the purchase agreement between the parties. Under the agreement, the Company is obligated to make additional payments of up to a maximum of \$4.3 million in contingent purchase price if FW Pharma achieves certain established financial and non-financial targets through January 31, 2005. In connection with this transaction, the Company recorded approximately \$9.4 million of excess cost over the fair value of the interest in the net assets acquired as goodwill. Goodwill is subject to impairment testing under SFAS No. 142.

On October 28, 2002, the Company acquired the assets of Pracon & HealthIQ, a provider of specialized sales and marketing services based in Reston, Virginia and Orange, California, for approximately \$1.7 million in cash. Pracon & HealthIQ was a division of Excerpta Medica, Inc. In connection with this transaction, the Company recorded approximately \$1.6 million of excess cost over the fair value of the interest in the net assets acquired as goodwill. Goodwill is subject to impairment testing under SFAS No. 142.

Effective July 1, 2001, the Company acquired EDYABE, a clinical research organization in Latin America, with offices in Argentina and Brazil, for approximately \$1.6 million in cash. In connection with this transaction, the Company recorded approximately \$1.4 million of excess cost over the fair value of the interest in the net assets acquired as goodwill. Goodwill is subject to impairment testing under SFAS No. 142.

During the three-month periods ended June 30, 2003 and December 31, 2002 the Company recorded facilities-related restructuring charges totaling \$3.5 million and \$5.9 million, respectively, as a result of changes in prior assumptions regarding certain leased facilities which were abandoned as part of the Company's June 2001 restructuring. The changes in prior assumptions were caused by a further deterioration in challenging real estate market conditions, which made it difficult to sub-lease the abandoned facilities at previously estimated rental rates.

In June 2001, the Company made certain reasonable assumptions based upon market conditions, which indicated that sub-lease payments for these abandoned facilities were probable. The June 2001 restructuring charge involved fourteen properties. The Company has been successful in exiting or subleasing eleven of those properties. After significant effort in trying to sub-lease the remaining properties in a time of a declining commercial real estate market, it became apparent to the Company during fiscal year 2003 that the original assumptions for the remaining three properties were no longer valid under current market conditions.

ANALYSIS BY SEGMENT

The Company evaluates its segment performance and allocates resources based on service revenue and gross profit (service revenue less direct costs), while other operating costs are evaluated on a geographical basis. Accordingly, the Company does not include selling, general, and administrative expenses, depreciation and amortization expense, interest income (expense), other income (expense), and income taxes expense in segment profitability. Service revenue, direct costs and gross profit on service revenue for fiscal years 2003, 2002, and 2001 were as follows:

IN THOUSANDS	2003	2002	2003 vs. 2002		2001	2002 vs. 2001	
			Increase (Decrease)	% Change		Increase (Decrease)	% Change
Service revenue:							
CRS	\$312,847	\$261,727	\$51,120	19.5%	\$240,501	\$21,226	8.8%
PCG	100,621	97,775	2,846	2.9%	80,796	16,979	21.0%
MMS	73,786	64,829	8,957	13.8%	54,277	10,552	19.4%
Perceptive	24,800	19,987	4,813	24.1%	11,986	8,001	66.8%
	<u>\$512,054</u>	<u>\$444,318</u>	<u>\$67,736</u>	15.2%	<u>\$387,560</u>	<u>\$56,758</u>	14.6%
Direct costs:							
CRS	\$199,359	\$175,120	\$24,239	13.8%	\$165,337	\$9,783	5.9%
PCG	75,964	71,466	4,498	6.3%	63,611	7,855	12.3%
MMS	49,829	43,464	6,365	14.6%	37,347	6,117	16.4%
Perceptive	15,156	15,873	(717)	-4.5%	11,465	4,408	38.4%
	<u>\$340,308</u>	<u>\$305,923</u>	<u>\$34,385</u>	11.2%	<u>\$277,760</u>	<u>\$28,163</u>	10.1%
Gross profit:							
CRS	\$113,488	\$86,607	\$26,881	31.0%	\$75,164	\$11,443	15.2%
PCG	24,657	26,309	(1,652)	-6.3%	17,185	9,124	53.1%
MMS	23,957	21,365	2,592	12.1%	16,930	4,435	26.2%
Perceptive	9,644	4,114	5,530	134.4%	521	3,593	689.6%
	<u>\$171,746</u>	<u>\$138,395</u>	<u>\$33,351</u>	24.1%	<u>\$109,800</u>	<u>\$28,595</u>	26.0%

For additional financial information on a segment and geographic basis, see Note 17 to the consolidated financial statements included in Item 8 of this annual report.

FISCAL YEAR ENDED JUNE 30, 2003 COMPARED WITH THE FISCAL YEAR ENDED JUNE 30, 2002

Service revenue increased by \$67.7 million, or 15.2%, to \$512.1 million for the fiscal year ended June 30, 2003 from \$444.3 million for fiscal year 2002. On a geographic basis, service revenue for the fiscal year ended June 30, 2003 was distributed as follows: The Americas \$268.6 million (52.5%), Europe \$225.6 million (44.0%), and Asia/Pacific \$17.9 million (3.5%). For the fiscal year ended June 30, 2002, service revenue was distributed as follows: The Americas \$255.4 million (57.5%), Europe \$171.7 million (38.6%), and Asia/Pacific \$17.2 million (3.9%). On a segment basis, CRS service revenue increased by \$51.1 million, or 19.5%, to \$312.8 million for the fiscal year ended June 30, 2003 from \$261.7 million in fiscal year 2002. Of the total 19.5% increase, approximately 6.7% was attributed to the positive impact of foreign currency fluctuations, with the remaining 12.8% primarily due to higher business volume in Phases IIIb and IV of the clinical trial business, increases in activity with the biotech client sector and the impact of changes in scope. PCG service revenue increased by \$2.8 million, or 2.9%, to \$100.6 million in the fiscal year ended June 30, 2003 from \$97.8 million in fiscal year 2002. Approximately 5.9% of PCG service revenue for fiscal year 2003 was attributed to the positive impact of foreign currency fluctuations. The increase in service revenue due to positive foreign currency fluctuations was offset by reduced revenue in fiscal year 2003. The reduction in year-over-year PCG service revenue was due primarily to reduced levels of discretionary spending by biopharmaceutical companies and a reduction in FDA enforcement activity, which impacted certain segments of PCG's business. MMS service revenue increased by \$8.9 million, or 13.8%, to \$73.8 million in fiscal year 2003 from \$64.8 million in the same period one year ago. Of the total 13.8% increase, approximately 7.8% was attributed to incremental revenue from the Pracon and HealthIQ acquisition completed during the second quarter of fiscal year 2003, while the remaining 6.0% was caused by an increase in the number of projects serviced by the group. Perceptive service revenue increased by \$4.8 million, or 24.1%, to \$24.8 million in fiscal year 2003 as compared with \$20.0 million in fiscal year 2002. Of the total 24.1% increase, approximately 18.8% was attributed to incremental revenue associated with the FW Pharma acquisition completed during the third quarter of this fiscal year, 3.5% was attributed to the positive impact of foreign currency fluctuations, and the remaining 1.8% was principally attributed to new business growth in web, voice, and data product offerings.

Reimbursement revenue consists of reimbursable out-of-pocket expenses incurred on behalf of, and is reimbursable, by clients. It does not yield any gross profit to the Company, nor does it have an impact on net income.

Direct costs increased by \$34.4 million, or 11.2%, to \$340.3 million in fiscal year 2003 from \$305.9 million in fiscal year 2002. On a segment basis, CRS direct costs increased by \$24.2 million, or 13.8%, to \$199.4 million for fiscal year 2003 from \$175.1 million in fiscal year 2002. Of the total 13.8% increase, approximately 6.4% was attributed to increased costs as a result of foreign currency fluctuations, and the remaining 7.4% was primarily due to higher labor costs associated with business growth. As a percentage of service revenue, CRS direct costs for fiscal year 2003 decreased by 3.2 percentage points to 63.7% from 66.9% over fiscal year 2002, primarily due to improved operational labor efficiencies, and leveraging of strong business growth. PCG direct costs increased \$4.5 million, or 6.3%, to \$76.0 million in fiscal year 2003 from \$71.5 in fiscal year 2002. Of the total 6.3% increase, approximately 1.6% was attributed to severance costs and the remaining 4.7% was primarily due to increased costs as a result of foreign currency fluctuations. As a percentage of service revenue, PCG direct costs for fiscal year 2003 increased by 2.4 percentage points to 75.5% in fiscal year 2003 from 73.1% in fiscal year 2002 primarily due to the year over year decline in revenue levels. MMS direct costs increased \$6.4 million, or 14.6%, to \$49.8 million in fiscal year 2003 from \$43.5 million in fiscal year 2002. Of the total 14.6% increase, approximately 5.5% was attributed to increased costs as a result of foreign currency fluctuations, 5.2% was attributed to incremental labor costs associated with the Pracon and HealthIQ acquisition and the remaining 3.9% was primarily due to increased labor costs associated with an increased number of projects serviced by the group. As a percentage of service revenue, MMS direct costs were 67.5% in fiscal year 2003 and 67.0% in fiscal year 2002. Perceptive direct costs decreased by \$0.7 million, or 4.5%, to \$15.2 million in fiscal year 2003 from \$15.9 million in fiscal year. An incremental increase in direct costs associated with the FW Pharma acquisition of approximately 4.9% was offset by a decrease in physician reader costs and lower labor costs. As a percentage of service revenue, Perceptive's direct costs for fiscal year 2003 decreased by 18.3 percentage points to 61.1% in fiscal year 2003 from 79.4% in the same period one year ago, primarily due to a more favorable business mix, lower physician reader costs, and better labor cost leveraging.

Selling, general and administrative ("SG&A") expenses increased by \$21.1 million, or 21.1%, to \$121.1 million in fiscal year 2003 from \$100.0 million in fiscal year 2002. Of the total 21.1% increase, approximately 8.7% was caused by foreign currency fluctuations, and approximately 2.7% was attributed to incremental expenses associated with the Pracon & HealthIQ and FW Pharma acquisitions, while the remaining 9.7% increase was driven primarily by increased selling and marketing expenses, higher research and development costs and the impact of recording \$2.4 million in severance costs. As a percentage of service revenue, SG&A increased by 1.2 percentage points to 23.7% in the fiscal year ended June 30, 2003 as compared with 22.5% in the fiscal year ended June 30, 2002.

The Company had 5,095 employees at the end of fiscal year 2003 and 4,930 employees at the end of fiscal year 2002. The increase was primarily due to the acquisitions of Pracon & HealthIQ and FW Pharma, as well as hiring of additional employees to support revenue growth.

Depreciation and amortization ("D&A") expense increased by \$2.8 million, or 15.4 %, to \$20.7 million in fiscal year 2003 from \$17.9 million in fiscal year 2002 primarily due to higher expenses as a result of foreign currency fluctuations and an increase in capital spending of \$6.2 million over fiscal year 2002. As a percentage of service revenue, D&A was 4.0% for fiscal years 2003 and 2002.

Income from operations increased marginally to \$20.6 million in fiscal year 2003 from \$20.5 million one year ago. Income from operations decreased as a percentage of service revenue to 4.0% in fiscal year 2003 from 4.6% in the last fiscal year due to the reasons noted in the preceding paragraphs. Facilities-related restructuring charges of \$9.4 million recorded during the fiscal year 2003 had an adverse impact on operating margin of 1.9 points.

Total other income/(loss) was \$(2.1) million in fiscal year 2003 and \$2.4 million in fiscal year 2002. The decrease was primarily due to a year-over-year increase in foreign exchange losses of \$4.5 million, as a result of a weakening of the U.S. dollar versus both the British Pound and the Euro.

The Company had an effective income tax rate of 39.2% in fiscal year 2003 compared with 39.3% in fiscal year 2002. Any future changes in the mix of taxable income in the different jurisdictions in which the Company operates could materially impact the Company's effective tax rate. The Company is projecting its fiscal year 2004 income tax rate to be around 39.5%.

FISCAL YEAR ENDED JUNE 30, 2002 COMPARED WITH THE FISCAL YEAR ENDED JUNE 30, 2001

Service revenue increased by \$56.8 million, or 14.6%, to \$444.3 million for the fiscal year ended June 30, 2002 from \$387.6 million for the same period in 2001. On a geographic basis, service revenue for fiscal year 2002 was distributed as follows: Americas \$255.4 million (57.5%), Europe \$171.7 million (38.6%), and Asia/pacific \$17.2 million (3.9%). In fiscal year 2001, service revenue was distributed as follows: Americas \$228.3 million (58.9%), Europe \$146.0 million (37.7%), and Asia/pacific \$13.3 million (3.4%). On a segment basis, CRS service revenue increased by \$21.2 million, or 8.8%, to \$261.7 million in fiscal year 2002 from \$240.5 million in fiscal year 2001. The year-over-year increase in CRS service revenue was driven mainly by a 21.7% increase in new business awards, principally in the biotech business and with Phase IIIb and Phase IV related studies. These increases in new business were offset in part by an unusually high rate of cancellations in fiscal year 2002, which in the vast majority of cases, were due to client safety and efficacy issues and budgetary reasons. PCG service revenue increased by \$17.0 million, or 21.0%, to \$97.8 million in fiscal year 2002 from \$80.8 million in fiscal year 2001 largely due to new business awards and incremental revenue resulting from fiscal year 2001 clinical pharmacology acquisitions, as well as solid increases in regulatory consulting in connection with recent increases in FDA enforcement activity. MMS service revenue increased by \$10.6 million, or 19.4%, to \$64.8 million in fiscal year 2002 as compared with \$54.3 million in fiscal year 2001 primarily due to an increase in the number of projects serviced by the business, which was in part attributable to an expansion of the MMS client base in the North America market. Perceptive service revenue increased by \$8.0 million, or 66.8%, to \$20.0 million in fiscal year 2002 from \$12.0 million in fiscal year 2001 principally due to a significant increase in new business awards from existing clients, and continued business expansion to new customers. These increases were attributable principally to growth in the web, voice, and data product offerings.

Reimbursement revenue consists of reimbursable out-of-pocket expenses incurred on behalf of, and is reimbursable by, clients. It does not yield any gross profit to the Company, nor does it have an impact on net income.

Direct costs increased by \$28.2 million, or 10.1%, to \$305.9 million in fiscal year 2002 from \$277.8 million in fiscal year 2001. On a segment basis, CRS direct costs increased \$9.8 million, or 5.9%, to \$175.1 million in fiscal year 2002 from \$165.3 million in fiscal year 2001 primarily due to higher labor costs associated with increased business volume. As a percentage of service revenue, CRS direct costs improved by 1.8 percentage points in fiscal year 2002, as compared with fiscal year 2001 primarily due to improved operational labor efficiencies and effective implementation of cost control measures as part of focused profitability improvement initiatives (e.g. enhanced billing practices and improved project management). PCG direct costs increased by \$7.9 million, or 12.3%, to \$71.5 million in fiscal year 2002 from \$63.6 million in fiscal year 2001 primarily due to inclusion of fiscal year 2001 acquisitions in the results for the full year and higher employee-related expenses associated with increased business volume across all business lines. As a percentage of service revenue, PCG direct costs improved by 5.6 percentage points as a result of greater fixed cost efficiency associated with revenue growth, as well as the impact of some higher margin regulatory projects in fiscal year 2002. MMS direct costs increased by \$6.1 million, or 16.4%, to \$43.5 million in fiscal year 2002, as compared with \$37.3 million in fiscal year 2001 primarily due to higher employee-related expenses required to support increased business volume. As a percentage of service revenue, MMS direct costs improved by 1.8 percentage points primarily due to increased efficiency and further improvements in direct cost management. Perceptive's direct costs increased by \$4.4 million, or 38.4%, to \$15.9 million in fiscal year 2002 from \$11.5 million in fiscal year 2001 primarily due to increased labor expense needed to support revenue growth within the business segment. As a percentage of service revenue, Perceptive's direct costs improved 16.3 percentage points, as compared with fiscal year 2001, primarily due to greater cost efficiency.

Selling, general and administrative ("SG&A") expense increased by \$11.3 million, or 12.7%, to \$100.0 million in fiscal year 2002 from \$88.7 million in fiscal year 2001 primarily due to increased labor costs associated with business growth (80% of total increase), marketing and promotion expense (13% of total increase), and other miscellaneous costs. As a percentage of service revenue, SG&A decreased by 0.4 percentage points.

The Company had approximately 4,930 employees at the end of fiscal year 2002 and 4,640 employees at the end of fiscal year 2001. The increase was primarily due to the acquisition of EDYABE, as well as hiring of additional employees needed to support revenue growth in all business segments.

Depreciation and amortization ("D&A") expense decreased \$3.6 million, or 16.6%, to \$17.9 million in fiscal year 2002 from \$21.5 million in fiscal year 2001 primarily due to foreign currency fluctuations compared with fiscal year 2001, adjustments which were made to the estimated useful lives of assets abandoned during the first quarter of fiscal year 2001 as part of the Company's restructuring plan, the current year impact of past restructuring activities, and the adoption of SFAS No. 142, under which the Company eliminated approximately \$0.8 million in amortization expense in fiscal year 2002. As a percentage of service revenue, D&A expense decreased to 4.0% in fiscal year 2002, from 5.5% in fiscal year 2001.

Income from operations increased \$27.4 million to \$20.5 million in fiscal year 2002 from a loss of \$6.9 million one year ago, primarily for the reasons noted in the preceding paragraphs, and the absence of restructuring charges in fiscal year 2002 when compared with fiscal year 2001. Income from operations as a percentage of service revenue increased to 4.6% in fiscal year 2002, as compared with a negative 1.8% in the last fiscal year.

Total other income decreased \$5.3 million, or 68.4%, to \$2.4 million in fiscal year 2002 from \$7.7 million in fiscal year 2001. The decrease was primarily due to lower worldwide interest rates and a reduction in foreign exchange gains related to the weakened U.S. dollar versus the Euro and the British Pound primarily during the fourth quarter of fiscal year 2002. The decrease was partially offset by a \$0.9 million gain from the sale of a building.

The Company had an effective income tax rate of 39.3% in fiscal year 2002 compared with 142.5% in fiscal year 2001. The reduction was primarily due to favorable changes in the mix of taxable income in the different jurisdictions where the Company operates and restructuring and other charges taken in fiscal year 2001, which were not benefited in fiscal year 2001. Without the impact of restructuring and other charges, the effective tax rate for fiscal year 2001 would have been 41.8%. As of June 30, 2002, there was approximately \$7.8 million of net operating loss carryforward tax benefits still remaining to be used in future years. As of June 30, 2002, there was a valuation reserve established of approximately \$10.0 million related to the benefit of these losses and other tax assets.

LIQUIDITY AND CAPITAL RESOURCES

Since its inception, the Company has financed its operations and growth, including acquisition costs, with cash flow from operations and proceeds from the sale of equity securities. Investing activities primarily reflect acquisition costs and capital expenditures for information systems enhancements.

Approximately 90% of the Company's contracts are fixed price, with some variable components, and range in duration from a few months to several years. Cash flow from these contracts typically consists of a down payment required to be paid at the time of contract execution with the balance due in installments over the contract's duration, usually on a milestone achievement basis. Revenue from these contracts is generally recognized as work is performed. As a result, cash receipts do not necessarily correspond to costs incurred and revenue recognized on contracts.

The Company's operating cash flow is heavily influenced by changes in the levels of billed and unbilled receivables and deferred revenue. These account balances as well as days sales outstanding in accounts receivable, net of deferred revenue, can vary based on contractual milestones and the timing and size of cash receipts. Days sales outstanding ("DSO") in accounts receivable, net of deferred revenue, was 45 days at June 30, 2003 compared with 56 days at June 30, 2002. The decrease in DSO in fiscal year 2003 as compared with fiscal 2002 was primarily due to improved billing practices and increased collection activities, as well as a higher level of deferred revenue. Accounts receivable, net of the allowance for doubtful accounts, was \$222.7 million (\$144.0 million in billed accounts receivable and \$78.7 million in unbilled accounts receivable) at June 30, 2003 and \$224.7 million (\$131.5 million in billed accounts receivable and \$93.2 million in unbilled accounts receivable) at June 30, 2002. Deferred revenue was \$130.7 million at June 30, 2003 and \$114.7 million at June 30, 2002. Days sales outstanding is calculated by adding the end-of-period balances for billed and unbilled account receivables, net of deferred revenue and allowances for doubtful accounts, then dividing the resulting amount by gross revenue (service revenue, reimbursement revenue, and investigator fees) for the most recent quarter, and multiplying the resulting fraction by the number of days in the quarter.

Net cash provided by operating activities for the fiscal year 2003 totaled \$47.8 million and was generated from \$10.7 million of net income, \$20.7 million related to depreciation and amortization expense, a \$15.4 million decrease in accounts receivable (net of allowance of doubtful accounts and deferred revenue), a \$6.5 million increase in current and non-current liabilities, a \$2.9 million increase in accounts payable, and \$0.6 million in minority interest in net income of a consolidated subsidiary, offset by a \$4.1 million increase in other assets, a \$3.4 million increase in deferred tax assets, and a \$1.5 million increase in prepaid and other current assets. Net cash provided by operating activities in fiscal year 2002 consisted of \$13.2 million of net income, \$17.9 million related to depreciation and amortization expense, an \$11.3 million increase in other liabilities, a \$3.8 million decrease in accounts receivable (net of the allowance for doubtful accounts and deferred revenue), and \$0.7 million of minority interest in the net income of a consolidated subsidiary, partially offset by a \$14.7 million decrease in accounts payable, a \$6.2 million increase in deferred income taxes, a \$2.7 million increase in prepaids and other assets, and a \$1.0 million gain on the disposal of assets. The \$25.5 million increase in net cash provided by operating activities for the year ended June 30, 2003 compared with the fiscal year 2002 was primarily attributable to a \$20.0 million decrease in accounts receivable and a \$17.7 million increase in accounts payable partially offset by a \$9.7 million decrease in deferred revenue, a \$2.8 million increase in non-cash charges for depreciation and amortization expense and a \$2.5 million decrease in net income. The year-over-year changes in accounts receivable and deferred revenue was a direct result of the Company's continued effort in billing and collections and the year-over-year change in accounts payable was primarily due to the timing of receipt of invoices.

Net cash used by investing activities for fiscal year 2003 totaled \$10.0 million and consisted of \$30.0 million used for capital expenditures (primarily computer software/hardware and leasehold improvements) and \$11.1 million used for the acquisitions of Pracon & HealthIQ and FW Pharma, offset by \$30.6 million of net proceeds from the sale of marketable securities and \$0.5 million in proceeds from the sale of assets. Net cash used by investing activities for fiscal year 2002 totaled \$63.9 million and consisted of \$40.3 million of net cash used to purchase marketable securities, \$23.8 million used primarily for software and hardware purchases across all business segments, and \$1.8 million used for a business acquisition, partly offset by \$1.9 million in proceeds from the sale of certain assets.

Net cash provided by financing activities for the fiscal year 2003 totaled \$3.7 million which was primarily generated by the proceeds from the issuance of common stock in conjunction with the Company's stock option and employee stock purchase plans. For fiscal year 2002, net cash provided by financing activities totaled \$3.3 million and consisted primarily of proceeds from the issuance of common stock in association with the Company's stock option and employee stock purchase plans.

The Company has a line of credit with ABN AMRO Bank, NV in the amount of Euro 12.0 million. This line-of-credit is not collateralized, is payable on demand, and bears interest at a rate ranging between 3% to 5%. The Company primarily entered into this line-of-credit to facilitate business transactions with the bank. At June 30, 2003, the Company had approximately Euro 12.0 million available under this line of credit.

The Company has other foreign lines-of-credit with banks totaling approximately \$1.7 million. These lines are used as overdraft protection and bear interest at rates ranging from 4% to 6%. The lines of credit are payable on demand and are supported by PAREXEL International Corporation. At June 30, 2003, the Company had approximately \$1.7 million available credit under these arrangements.

The Company has a cash pooling arrangement with ABN AMRO Bank. Pooling occurs when debit balances are offset against credit balances and the net position is used as a basis by the bank for interest calculation. Each legal entity owned by the Company and party to this arrangement remains the owner of either a credit or debit balance. Therefore, interest income is earned in legal entities with credit balances, while interest expense is charged in legal entities with debit balances. Based on the pool's overall balance, the bank then recalculates the overall interest to be charged or earned, compares this amount with the sum of already charged/earned interest amounts per account and additionally pays/charges the difference. Interest income and interest expense are recorded separately in the Company's consolidated statements of operations.

The Company's primary cash needs are for the payment of salaries and fringe benefits, hiring and recruiting expenses, business development costs, acquisition-related costs, capital expenditures, and facilities-related expenses. The Company's principal source of cash is from contracts with clients. If the Company is unable to generate new contracts with existing and new clients and/or if the level of contract cancellations increases, revenue and cash flow will be adversely affected (see "Risk Factors" for further detail). Absent a material adverse change in the level of the Company's new business bookings or contract cancellations, PAREXEL believes that its existing capital resources together with cash flow from operations and borrowing capacity under existing lines of credit will be sufficient to meet its foreseeable cash needs.

In the future, the Company expects to consider acquiring businesses to enhance its service offerings, expand its therapeutic expertise, and/or increase its global presence. Any such acquisitions may require additional external financing, and the Company may from time to time seek to obtain funds from public or private issuance of equity or debt securities. The Company may be unable to secure such financing on terms acceptable to the Company.

CONTINGENT LIABILITIES AND GUARANTEES

The Company's contractual obligations and commitments for fiscal years subsequent to June 30, 2003 are as follows:

(\$ IN THOUSANDS)	2004	2005	2006	2007	2008	Thereafter	2008
Operating leases	\$27,666	\$27,439	\$23,434	\$19,510	\$17,708	\$58,054	\$173,811
Obligations under capital leases	97	105	114	92	-	-	408
	<u>\$27,763</u>	<u>\$27,544</u>	<u>\$23,548</u>	<u>\$19,602</u>	<u>\$17,708</u>	<u>\$58,054</u>	<u>\$174,219</u>

The Company expects capital expenditures to total approximately \$27.0 million in fiscal year 2004.

In association with the FW Pharma acquisition as discussed in Note 3 to the consolidated financial statements included in Item 8 of this annual report, the Company is obligated to make a maximum additional payment of \$4.3 million in contingent purchase price if FW Pharma achieves certain established financial and non-financial targets through January 31, 2005.

The Company has letter-of-credit agreements with banks totaling approximately \$1.0 million guaranteeing performance under various operating leases and vendor agreements.

OFF-BALANCE SHEET ARRANGEMENTS

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to the Company.

FOREIGN CURRENCY EXCHANGE RATES

The Company derived approximately 48% of its service revenue for fiscal year 2003, 43% of its service revenue for fiscal year 2002 and 41% of its service revenue for fiscal year 2001, from operations outside of the U.S. The Company does not have significant operations in countries in which the economy is considered to be highly inflationary. The Company's financial statements are denominated in U.S. dollars, and accordingly, changes in exchange rates between foreign currencies and the U.S. dollar will affect the translation of such subsidiaries' financial results into U.S. dollars for purposes of reporting the Company's consolidated financial results.

The Company may be subjected to foreign currency transaction risk when the Company's foreign subsidiaries enter into contracts denominated in a currency other than the foreign subsidiary's functional (local) currency. During fiscal years 2003 and 2002, the Company recorded foreign-exchange losses of \$1.9 million and gains of \$0.2 million, respectively. To the extent the Company is unable to shift the effects of currency fluctuations to its clients, foreign exchange fluctuations could have a material effect on the Company's results of operations. The Company occasionally enters into currency exchange contracts to offset the impact of currency fluctuations. These currency exchange contracts generally have maturity dates ranging from one to six months. The Company does not expect gains or losses on these contracts to have a material impact on its financial results (see Note 2 to the consolidated financial statements included in Item 8 of this annual report).

INFLATION

The Company believes the effects of inflation generally do not have a material adverse impact on its operations or financial condition.

RELATED PARTY TRANSACTIONS

The Company contributed the shares of stock of FWPS Group Limited, a company organized under the laws of the United Kingdom, which it acquired in January 2003, to its indirect majority owned subsidiary, Perceptive Informatics, Inc., in July 2003. Perceptive issued shares of common stock to PAREXEL International Trust, a wholly owned subsidiary of the Company, as consideration for this contribution. As a result of the transaction, the Company's ownership in Perceptive increased from 97.4% to 98.2%. Certain officers and Directors of the Company own less than 2% of the issued and outstanding common stock of Perceptive.

During the years ended June 30, 2003 and 2002, certain members of the Company's Board of Directors were affiliated with certain companies in which PAREXEL made investments in fiscal year 2001. The total sum of all of these investments by PAREXEL was \$0.9 million. During the year ended June 30, 2002 and a portion of the year ended June 30, 2003, a member of the Company's Board of Directors was also a director of one of the Company's customers. Revenue recognized from this customer in fiscal year 2002 was \$16.0 million. The accounts receivable balance at June 30, 2002 from this customer was \$8.6 million. Related party amounts included in accounts receivable were on standard terms and manner of settlement.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

MARKET RISK

Market risk is the potential loss arising from adverse changes in market rates and prices, such as foreign currency rates, interest rates, and other relevant market rate or price changes. In the ordinary course of business, the Company is exposed to market risk resulting from changes in foreign currency exchange rates, and the Company regularly evaluates its exposure to such changes. The Company's overall risk management strategy seeks to balance the magnitude of the exposure and the costs and availability of appropriate financial instruments.

FOREIGN CURRENCY EXCHANGE RATES

The Company may be subjected to foreign currency transaction risk when the Company's foreign subsidiaries enter into contracts or incur liabilities denominated in a currency other than the foreign subsidiary's functional currency. For the year ended June 30, 2003, approximately 20.4% of total service revenue was denominated in British pounds and approximately 21.9% of total service revenue was denominated in Euros. The Company enters into foreign currency exchange contracts to offset the impact of currency fluctuations. Such contracts are not treated as hedges for accounting purposes. The notional contract amount of outstanding currency exchange contracts was approximately \$28.3 million at June 30, 2003. The potential loss in the fair value of these currency exchange contracts that would result from a hypothetical change of 10% in exchange rates would be approximately \$2.9 million.

INTEREST RATES

The Company's exposure to interest rate changes is minimal as the level of long-term debt the Company has is minimal. Long-term debt was approximately \$0.6 million as of June 30, 2003 and \$0.4 million as of June 30, 2002.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

PAREXEL INTERNATIONAL CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS

For the years ended June 30,
(in thousands, except per share data)

	2003	2002	2001
Service revenue	\$512,054	\$444,318	\$387,560
Reimbursement revenue	107,161	120,606	93,728
TOTAL REVENUE	619,215	564,924	481,288
Costs and expenses:			
Direct costs	340,308	305,923	277,760
Reimbursable out-of-pocket expenses	107,161	120,606	93,728
Selling, general and administrative	121,111	100,009	88,745
Depreciation and amortization	20,656	17,893	21,453
Restructuring charges	9,374	-	6,462
TOTAL COSTS	598,610	544,431	488,148
INCOME (LOSS) FROM OPERATIONS	20,605	20,493	(6,860)
Interest income	4,403	2,693	2,677
Interest expense	(3,240)	(1,452)	(96)
Other income (loss), net	(3,281)	1,200	5,151
TOTAL OTHER INCOME (LOSS)	(2,118)	2,441	7,732
Income before provision for income taxes	18,487	22,934	872
Provision for income taxes	7,250	9,013	1,243
Minority interest	575	686	454
NET INCOME (LOSS)	\$10,662	\$13,235	\$(825)
Earnings (loss) per share:			
Basic	\$0.42	\$0.53	\$(0.03)
Diluted	\$0.42	\$0.52	\$(0.03)
Weighted average shares			
Basic	25,371	24,928	24,637
Diluted	25,683	25,582	24,637

The accompanying notes are an integral part of the consolidated financial statements.

PAREXEL INTERNATIONAL CORPORATION
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)

	June 30,	
	2003	2002
ASSETS		
Current assets:		
Cash and cash equivalents	\$69,734	\$22,479
Marketable securities (Note 4)	12,990	43,630
Billed and unbilled accounts receivable, net (Note 5)	222,726	224,713
Prepaid expenses	12,087	8,688
Current deferred tax assets	27,604	21,642
Other current assets	4,936	6,388
Total current assets	350,077	327,540
Property and equipment, net (Note 6)	61,924	47,624
Goodwill (Note 2)	29,803	12,257
Other intangible assets, net (Note 2)	5,763	2,506
Non-current deferred tax assets	10,043	11,201
Other assets	6,627	6,033
Total assets	\$464,237	\$407,161
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Notes payable and current portion of long-term debt	\$118	\$422
Accounts payable	14,462	11,858
Deferred revenue	130,650	114,723
Accrued expenses	13,766	12,513
Accrued restructuring charges (Note 7)	8,750	3,301
Accrued employee benefits and withholdings	37,849	31,713
Current deferred tax liabilities	2,557	2,538
Income taxes payable	1,801	7,361
Other current liabilities	5,778	5,091
Total current liabilities	215,731	189,520
Long-term debt	644	432
Non-current deferred tax liabilities	10,674	9,268
Other liabilities	6,092	5,087
Total liabilities	233,141	204,307
Commitments and contingencies (Note 14)		
Minority interest in subsidiary	3,996	2,777
Stockholders' equity:		
Preferred stock--\$.01 par value; shares authorized:		
5,000,000 at June 30, 2003 and June 30, 2002;		
Series A Junior Participating Preferred Stock - 50,000 shares		
designated, none issued and outstanding		
Common stock--\$.01 par value; shares authorized:		
50,000,000 at June 30, 2003 and 2002; shares		
issued: 26,683,055 at June 30, 2003 and		
26,033,808 at June 30, 2002; shares outstanding:		
25,822,055 at June 30, 2003 and 25,172,808 at June 30, 2002	267	261
Additional paid-in capital	174,734	167,829
Treasury stock, at cost; 861,000 shares at June 30, 2003 and 2002	(8,165)	(8,165)
Retained earnings	63,117	52,455
Accumulated other comprehensive loss	(2,853)	(12,303)
Total stockholders' equity	227,100	200,077
Total liabilities and stockholders' equity	\$464,237	\$407,161

The accompanying notes are an integral part of the consolidated financial statements.

PAREXEL INTERNATIONAL CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(in thousands, except share and per share data)

	<u>Common Stock</u>					Accum. Other		
	Number Of Shares	Par Value	Add Additional Paid-in Capital	Treasury Stock, At Cost	Retained Earnings (Accum. Deficit)	Compre- hensive Income (Loss)	Total Stock- holders' Equity	Compre- hensive Income/ (Loss)
Balance at June 30, 2000	24,719,158	\$254	\$162,057	\$(6,424)	\$40,173	\$(9,927)	\$186,133	<u>\$(1,960)</u>
Shares issued under stock option/ purchase plans	266,062	3	1,874				1,877	
Income tax benefit from exercise of stock options			227				227	
Shares repurchased	(210,000)			(1,758)			(1,758)	
Foreign currency translation adjustment						(7,704)	(7,704)	(7,704)
Retirement of treasury stock			(17)	17				
Elimination of net income of subsidiary for change in fiscal year					(128)		(128)	
Net loss					(825)		(825)	(825)
Balance at June 30, 2001	24,775,220	\$257	\$164,141	\$(8,165)	\$39,220	\$(17,631)	\$177,822	<u>\$(8,529)</u>
Shares issued under stock option/ purchase plans	397,588	4	3,263				3,267	
Income tax benefit from exercise of stock options			425				425	
Foreign currency translation adjustment						5,328	5,328	5,328
Net income					13,235		13,235	13,235
Balance at June 30, 2002	25,172,808	\$261	\$167,829	\$(8,165)	\$52,455	\$(12,303)	\$200,077	<u>\$18,563</u>
Shares issued under stock option/ purchase plans	411,154	4	3,797				3,801	
Shares issued for acquisitions	238,095	2	2,887				2,889	
Income tax benefit from exercise of stock options			221				221	
Foreign currency translation adjustment						9,450	9,450	9,450
Net income					10,662		10,662	10,662
Balance at June 30, 2003	25,822,057	\$267	\$174,734	\$(8,165)	\$63,117	\$(2,853)	\$227,100	<u>\$20,112</u>

The accompanying notes are an integral part of the consolidated financial statements.

PAREXEL INTERNATIONAL CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

	For the years ended June 30,		
	2003	2002	2001
CASH FLOW FROM OPERATING ACTIVITIES:			
Net income (loss)	\$10,662	\$13,235	\$(825)
Adjustments to reconcile net income to net cash provided (used) by operating activities:			
Minority interest in net income of consolidated subsidiary	575	686	454
Depreciation and amortization	20,656	17,893	21,453
(Gain) loss on disposal of assets	122	(963)	(108)
Deferred income taxes	(3,379)	(6,206)	4,063
Allowance for doubtful accounts	1,391	47	875
Change in assets and liabilities, net of effects from acquisitions:			
Accounts receivable	3,114	(16,911)	(46,901)
Prepaid expenses and other current assets	(1,469)	(1,962)	1,163
Other assets	(4,144)	(737)	(2,130)
Accounts payable	2,935	(14,727)	6,316
Deferred revenue	10,904	20,614	7,354
Other current liabilities	5,445	10,205	(16)
Other liabilities	1,005	1,140	2,665
Net cash provided (used) by operating activities	<u>47,817</u>	<u>22,314</u>	<u>(5,637)</u>
CASH FLOW FROM INVESTING ACTIVITIES:			
Purchases of marketable securities	(204,589)	(364,594)	(93,120)
Proceeds from sale of marketable securities	235,229	324,323	126,735
Purchases of property and equipment	(29,985)	(23,808)	(18,145)
Acquisition of a business, net of cash acquired	(11,131)	(1,793)	(2,994)
Proceeds from sale of assets	488	1,945	915
Net cash provided (used) by investing activities	<u>(9,988)</u>	<u>(63,927)</u>	<u>13,391</u>
CASH FLOW FROM FINANCING ACTIVITIES:			
Proceeds from issuance of common stock	3,801	3,267	1,878
Payments to repurchase common stock	-	-	(1,758)
Borrowings (repayments) under lines of credit and long-term debt	(92)	45	(129)
Proceeds from issuance of subsidiary's common stock	-	-	386
Net cash provided by financing activities	<u>3,709</u>	<u>3,312</u>	<u>377</u>
Elimination of net loss of a subsidiary for change in fiscal year	-	-	(128)
Effect of exchange rate changes on cash and cash equivalents	<u>5,717</u>	<u>3,190</u>	<u>(3,921)</u>
Net increase (decrease) in cash and cash equivalents	47,255	(35,111)	4,082
Cash and cash equivalents at beginning of year	<u>22,479</u>	<u>57,590</u>	<u>53,508</u>
Cash and cash equivalents at end of year	<u>\$69,734</u>	<u>\$22,479</u>	<u>\$57,590</u>

The accompanying notes are an integral part of the consolidated financial statements

PAREXEL INTERNATIONAL CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(in thousands)

For the years ended June 30,
2003 2002 2001

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid during the year for:

Interest	\$3,236	\$1,448	\$50
Income taxes	\$16,343	\$9,975	\$3,202

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING ACTIVITIES:

Asset purchased under capital lease	<u>-</u>	<u>\$525</u>	<u>-</u>
Fair value of assets acquired and goodwill	\$21,294	\$2,928	\$5,550
Liabilities and minority interest assumed	<u>(7,213)</u>	<u>(1,135)</u>	<u>(2,556)</u>
Cash paid and common stock issued for acquisitions	<u>\$14,081</u>	<u>\$1,793</u>	<u>\$2,994</u>

SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES:

Income tax benefit from exercise of stock options	\$221	\$425	\$227
---	-------	-------	-------

The accompanying notes are an integral part of the consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. DESCRIPTION OF BUSINESS

The Company is a leading biopharmaceutical services company, providing a broad range of expertise in clinical research, medical marketing, consulting and informatics and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries. The Company's primary objective is to provide solutions for managing the biopharmaceutical product lifecycle with the goal of reducing the time, risk and cost associated with the development and commercialization of new therapies. Since its founding in 1983, PAREXEL has developed significant expertise in processes and technologies supporting this strategy. The Company's product and service offerings include: clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, performance improvement, industry training and publishing, web-based portal solutions, IVRS, CTMS, electronic data capture solutions, medical imaging services, and other drug development consulting services. The Company believes that its integrated services, depth of therapeutic area expertise, access to patients, and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The consolidated financial statements include the accounts of PAREXEL International Corporation, its wholly owned and majority-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated.

The Company changed the fiscal year end for one of its subsidiaries, MMS, from May 31 to June 30 in fiscal year 2001. The effect of this change resulted in the reduction of retained earnings in the amount of \$0.1 million during fiscal year 2001.

Reclassifications

Certain fiscal year 2002 amounts have been reclassified to conform to the fiscal year 2003 presentation.

Accounting Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and disclosures of contingent assets and liabilities. Actual results may differ from those estimates.

Revenue

In the Company's CRS, PCG and MMS business units, fixed-price contract revenue is recognized as services are performed. The Company measures progress for fixed price contracts using the concept of proportional performance based upon a direct labor cost-to-cost methodology or by the unit based output method. Under the proportional performance method, revenue is recognized based upon an estimate by comparing the ratio of direct labor costs incurred to total estimated direct labor costs. Under the unit based output method, output units are predefined in the contract and revenue is recognized based upon completion of such output units.

In the Company's Perceptive business unit, software revenue is recognized based on percentage of completion in accordance with Statement of Position ("SOP") 97-2 "Software Revenue Recognition" and the relevant guidance provided by SOP 81-1 "Accounting for Performance of Construction-Type and Certain Production-Type Contracts", due to the significant nature of customization of each project.

Revenue related to contract modifications is recognized when realization is assured and the amounts are reasonably determinable. Adjustments to contract cost estimates are made in the periods in which the facts that require the revisions become known. When the revised estimates indicate a loss, such loss is provided in the current period in its entirety. Unbilled accounts receivable represent revenue recognized in excess of amounts billed. Deferred service revenue represents amounts billed in excess of revenue recognized.

Effective January 1, 2002, the Company adopted EITF 01-14 Income Statement Characterization of Reimbursements Received for Out-of-Pocket Expenses Incurred. These out-of-pocket expenses are reflected in the Company's Consolidated Statements of Operations under "Reimbursement Revenue" and "Reimbursable Out-of-Pocket Expenses".

As is customary in the industry, the Company routinely subcontracts on behalf of its clients with independent physician investigators in connection with clinical trials. These investigator fees are not reflected in PAREXEL's Service Revenue, Reimbursement Revenue, Reimbursable Out-of-Pocket Expenses, and/or Direct Costs, since such fees are reimbursed by customers on a "pass through basis", without risk or reward to the Company. The amounts of these investigator fees were \$78.6 million, \$74.6 million and \$56.2 million for the fiscal years ended June 30, 2003, 2002 and 2001, respectively.

Cash, Cash Equivalents, Marketable Securities, and Financial Instruments

The Company considers all highly liquid investments purchased with original maturities of 30 days or less to be cash equivalents. Marketable securities include securities purchased with original maturities of greater than 30 days. Marketable securities are classified as "available for sale" and are carried at fair market value, which approximates amortized cost.

Concentration of Credit Risk

Financial instruments, which may potentially expose the Company to concentrations of credit risk, include trade accounts receivable. However, the Company maintains reserves for potential credit losses and such losses, in the aggregate, have not exceeded management expectations. In fiscal years 2003 and 2002, one client, AstraZeneca PLC, accounted for 11% of consolidated service revenue. In fiscal year 2001, Novartis AG accounted for 10% of consolidated service revenue. The accounts receivable balance for AstraZeneca PLC was \$28.2 million at June 30, 2003 and \$23.4 million at June 30, 2002.

Property and Equipment

Property and equipment is stated at cost. Depreciation is provided on the straight-line method based on estimated useful lives of 40 years for buildings, 3 to 8 years for computer hardware and software, and 5 years for office furniture, fixtures and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the improvements or the remaining lease term. Repair and maintenance costs are expensed as incurred.

Goodwill

Effective July 1, 2002, the Company adopted the provisions of SFAS No. 142, "Goodwill and Other Intangible Assets". Under this statement, goodwill as well as certain other intangible assets, determined to have an indefinite life, are no longer amortized. Instead, these assets are reviewed for impairment at least annually or more frequently if an event occurs or circumstances change that would more likely than not reduce the carrying value of the reporting unit below its fair value. The Company has performed its annual impairment test, with no evidence of impairment to the Company's goodwill for fiscal years 2003 and 2002.

The changes in the carrying amount of goodwill for fiscal years 2003 and 2002 were as follows (in thousands):

Carrying amount as of June 30, 2001	\$12,381
Add: EDYABE	1,400
Effect of change in rates used for translation	<u>(1,524)</u>
Carrying amount as of June 30, 2002	\$12,257
Add: Pracon & HealthIQ	1,632
FW Pharma	9,445
Effect of change in rates used for translation and adjustments	<u>6,469</u>
Carrying amount as of June 30, 2003	<u>\$29,803</u>

The pro forma effect on fiscal year 2001 earnings of excluding amortization expense, net of tax, was as follows:

(\$ in thousands, except per share data)

	2001
Net loss, as reported	\$(825)
Add: goodwill amortization, net of tax	<u>800</u>
Pro forma net loss	<u><u>\$(25)</u></u>
Basis loss per common share:	
Net loss, as reported	\$(0.03)
Pro forma net loss	\$0.00

Intangible Assets

Intangible assets consist primarily of technology and customer lists acquired in association with the FW Pharma acquisition (see Note 3 to the consolidated financial statements included in Item 8 of this annual report for more detail). The estimated useful lives for all intangible assets are between 3 to 10 years.

Intangible assets of \$5.8 million and \$2.5 million are net of accumulated amortization of \$0.6 million and \$0.2 million as of June 30, 2003 and 2002, respectively. Amortization expense was \$0.5 million, \$0.06 million and \$0.2 million for the fiscal years ended June 30, 2003, 2002, and 2001, respectively.

Income Taxes

Deferred income tax assets and liabilities are recognized for the expected future tax consequences (utilizing current tax rates) of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Deferred tax assets are recognized for the estimated future tax benefits of deductible temporary differences and tax operating loss and credit carryforwards and are net of valuation allowances established in jurisdictions where the realization of those benefits is questionable. Deferred income tax expense represents the change in the net deferred tax asset and liability balances.

Foreign Currency

Assets and liabilities of the Company's international operations are translated into U.S. dollars at exchange rates that are in effect on the balance sheet date and equity accounts are translated at historical exchange rates. Income and expense items are translated at average exchange rates, which are in effect during the year. Translation adjustments are accumulated in other comprehensive loss as a separate component of stockholders' equity in the consolidated balance sheet. Transaction gains and losses are included in other income, in the consolidated statements of operations. Transaction gains/(losses), net of foreign currency exchange contract gains and losses were \$(1.9) million, \$0.2 million and \$5.0 million in fiscal years 2003, 2002, 2001, respectively.

Earnings Per Share

Earnings per share has been calculated in accordance with SFAS No. 128, "Earnings per Share." Basic earnings per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of common shares plus the dilutive effect of outstanding stock options and shares issuable under the employee stock purchase plan.

Stock-Based Compensation

The Company accounts for employee stock awards using the intrinsic value based method as prescribed by Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees", as described by FASB Interpretation No. 44. Accordingly, no compensation expense is recognized because the exercise price of the Company's stock options was equal to the market price of the underlying stock on the date of grant. The Company has adopted the provisions of SFAS No. 123, "Accounting for Stock-Based Compensation", as amended by SFAS No. 148 for disclosure purposes only.

The fair value for options granted was estimated at the time of the grant using the Black-Scholes option pricing model with the following weighted-average assumptions for the three years ended June 30, 2003, 2002 and 2001: Risk free interest rates of 3.32% in fiscal year 2003, 4.08% in fiscal year 2002 and 5.52% in fiscal year 2001; dividend yield of 0.0% for each year; volatility factor of the expected market price of the Company's common stock of 57% for fiscal year 2003, 64% for fiscal year 2002 and 67% for fiscal year 2001; and an average holding period of 5 years for fiscal year 2003 and 6 years for fiscal years 2002 and 2001. During the fiscal years 2003, 2002 and 2001, the weighted-average grant-date fair value of the stock options granted were \$11.19, \$13.19 and \$11.17 per share, respectively.

If the compensation cost for the Company's stock options and the employee stock purchase plan had been determined based on the fair value at the date of grant, as prescribed in SFAS No. 123, the Company's net income and net income per share would have been as follows:

(\$ in thousands, except per share data)	2003	2002	2001
Net income (loss), as reported	\$10,662	\$13,235	\$(825)
Deduct total stock-based compensation, net of tax	2,154	5,858	4,068
Pro forma net income (loss)	<u>\$8,508</u>	<u>\$7,377</u>	<u>\$(4,893)</u>
Pro forma net income (loss) per share:			
Basic	\$0.34	\$0.30	\$(0.20)
Diluted	\$0.33	\$0.29	\$(0.20)

As stock options vest over several years and additional stock option grants are expected to be made each year, the above pro forma disclosures are not necessarily representative of pro forma effects on results of operations for future periods.

Financial Instruments

From time to time, the Company enters into currency exchange contracts to hedge foreign currency exposures. These currency exchange contracts were entered into as economic hedges, which have not been designated as hedges for accounting purposes as defined under FAS 133.

Realized gains or losses on currency exchange contracts, acquired for the purpose of reducing exposure to currency fluctuations associated with expected cash flows denominated in currencies other than functional currencies, are reflected in other income, in the consolidated statements of operations. Currency exchange contracts are marked to market with the unrealized gain or loss reflected in other income, in the consolidated statements of operations.

Recently Issued Accounting Standards

In May 2003, the Financial Accounting Standard Board ("FASB") issued SFAS No. 150, "Accounting for Certain Instruments with Characteristics of both Liabilities and Equity" ("SFAS 150"), which establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity. SFAS 150 is effective for financial instruments entered into or modified after May 31, 2003, and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003. The Company's adoption of the initial recognition and initial measurement provisions of SFAS 150, effective June 1, 2003, did not have a material impact on the Company's results of operations or financial position.

In April 2003, the FASB issued SFAS No 149, "Derivatives and Hedging, an Amendment of FASB Statement 133" ("SFAS 149"). This statement amends and clarifies accounting for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities under Statement 133, Accounting for Derivative Instruments and Hedging Activities. The changes in this Statement improve financial reporting by requiring that contracts with comparable characteristics be accounted for similarly. In particular, this Statement clarifies under what circumstances a contract with an initial net investment meets the characteristic of a derivative of Statement 133, clarifies when a derivative contains a financing component, amends the definition of an "underlying" to conform it to language used in FASB Interpretation No. 45, "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others", and amends certain other existing pronouncements. Those changes will result in more consistent reporting of contracts as either derivatives or hybrid instruments. This Statement is effective for contracts entered into or modified after June 30, 2003 and for hedging relationships designated after June 30, 2003. The Company will adopt SFAS 149 effective July 1, 2003, and does not expect that the provisions of SFAS 149 will have a material impact on the Company's results of operations or financial position.

In January 2003, the Emerging Issues Task Force ("EITF"), published EITF Issue 00-21 ("EITF 00-21"), "Revenue Arrangements with Multiple Deliverables", which requires companies to determine whether an arrangement involving multiple deliverables contains more than one unit of accounting. In applying EITF 00-21, revenue arrangements with multiple deliverables should be divided into separate units of accounting if the deliverables in the arrangement meet certain criteria. Arrangement consideration should be allocated among the separate units of accounting based on their relative fair values. This issue is effective for revenue arrangements entered into in fiscal periods beginning after June 15, 2003. The Company does not believe the adoption of EITF 00-21 will have a material impact on the Company's results of operations or financial position.

In January 2003, the FASB issued Interpretation No 46 ("FIN 46"), "Consolidation of Variable Interest Entities", to expand upon and strengthen existing accounting guidance that addresses when a company should include in its financial statements the assets, liabilities and activities of another entity. Until now, a company generally has included another entity in its consolidated financial statements only if it controlled the entity through voting interests. FIN 46 changes that guidance by requiring a variable interest entity, as defined, to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity's activities or is entitled to receive a majority of the entity's residual returns or both. FIN 46 also requires disclosure about variable interest entities that the company is not required to consolidate but in which it has a significant variable interest. The consolidation requirements of FIN 46 apply immediately to variable interest entities created after January 31, 2003 and to older entities in the first fiscal year or interim period beginning after June 15, 2003. Certain of the disclosure requirements apply in all financial statements issued after January 31, 2003, regardless of when the variable interest entity was established. The application of the consolidation of variable interest entities created after January 31, 2003 and the disclosure requirements of FIN 46 did not have a material effect on the Company's financial position or its results of operations and the Company is in the process of assessing the impact, if any, the consolidation of variable interest entities created prior to January 31, 2003 will have on its financial position and results of operations.

In December 2002, the FASB issued SFAS No 148, "Accounting for Stock-Based Compensation Transition Disclosure" ("SFAS 148"), An Amendment of FASB Statement No. 123. This statement provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS 148 amends the disclosure requirements of Statement No. 123 to require more prominent and more frequent disclosure in financial statements regarding the effects of stock-based compensation. The provisions of SFAS 148 are effective for fiscal years ending after December 15, 2002 and the interim disclosure provisions are effective for financial reports containing financial statements for interim periods beginning after December 15, 2002. The Company will continue to apply Accounting Principles Board Opinion No. 25 as the method used to account for stock-based employee compensation arrangements, where applicable, but adopted SFAS 148 on January 1, 2003 and included the disclosure modifications in these consolidated financial statements. The adoption of this Statement did not have a material effect on the Company's financial position or its results of operations.

In November 2002, the FASB issued FIN 45, "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others". FIN 45 requires that upon issuance of a guarantee, the guarantor must recognize a liability for the fair value of the obligation it assumes under the guarantee. The disclosure provisions of FIN 45 are effective for financial statements of interim or annual periods ending after December 15, 2002. The provisions for initial recognition and measurement are effective on a prospective basis for guarantees that are issued or modified after December 31, 2002, irrespective of a guarantor's year-end. The adoption of FIN 45 did not impact the Company's consolidated results of operations or financial position.

In June 2002, the FASB issued SFAS No 146 ("SFAS 146"), Costs Associated with Exit or Disposal Activities. SFAS 146 nullifies EITF Issue No. 94-3, Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity. SFAS 146 requires that a liability for a cost associated with an exit or disposal activity be recognized and measured initially at fair value only when the liability is incurred. SFAS 146 is effective for exit or disposal activities that are initiated after December 31, 2002 and became effective in the third quarter ended March 31, 2003. The adoption of SFAS 146 did not impact the Company's financial position or results of its operations.

NOTE 3. ACQUISITIONS

Fiscal Year 2003

On January 31, 2003, the Company acquired 100% of the outstanding stock of FWPS Group Limited (FW Pharma), a provider of software for clinical trial management systems in Birmingham, United Kingdom, for approximately \$11.9 million in the form of a combination of cash and shares of the Company's common stock. The Company originally issued an aggregate of 238,095 shares (valued at approximately \$3.0 million) of its common stock to stockholders of FWPS Group Limited in connection with the acquisition. Of these shares, 32,854 shares were surrendered back to the Company by FW Pharma stockholders pursuant to the purchase price adjustment provisions in the purchase agreement between the parties. Under the agreement, the Company is obligated to make additional payments of up to a maximum of \$4.3 million in contingent purchase price if FW Pharma achieves certain established financial and non-financial targets through January 31, 2005. In connection with this transaction, the Company recorded approximately \$9.4 million of excess cost over the fair value of the interest in the net assets acquired as goodwill. Goodwill is subject to impairment testing under SFAS No. 142.

On October 28, 2002, the Company acquired the assets of Pracon & HealthIQ, a provider of specialized sales and marketing services based in Reston, Virginia and Orange, California, for approximately \$1.7 million in cash. Pracon & HealthIQ was a division of Excerpta Medica, Inc. In connection with this transaction, the Company recorded approximately \$1.6 million of excess cost over the fair value of the interest in the net assets acquired as goodwill. Goodwill is subject to impairment testing under SFAS No. 142.

Fiscal Year 2002

Effective July 1, 2001, the Company acquired EDYABE, a clinical research organization in Latin America, with offices in Argentina and Brazil, for approximately \$1.6 million in cash. In connection with this transaction, the Company recorded approximately \$1.4 million of excess cost over the fair value of the interest in the net assets acquired as goodwill. Goodwill is subject to impairment testing under SFAS No. 142.

Fiscal Year 2001

On September 29, 2000, the Company acquired a clinical pharmacology unit located in Northwick Park Hospital in Harrow, U.K from Glaxo Wellcome. The fair value of the assets acquired and the amount the Company paid for this transaction was nominal. As such, there was no goodwill recorded for this transaction.

Effective September 1, 2000, the Company acquired 60% of FARMOVS, a clinical pharmacology research business and bioanalytical laboratory located in Bloemfontein, South Africa for approximately \$3.0 million in cash. In connection with this transaction, the Company recorded approximately \$2.0 million related to the excess cost over the fair value of the interest in the net assets acquired as goodwill. Goodwill is subject to impairment testing under SFAS No. 142.

NOTE 4. MARKETABLE SECURITIES

Available-for-sale securities included in marketable securities at June 30, 2003 and 2002, consisted entirely of municipal debt and money market securities. At June 30, 2003, all available-for-sale securities were scheduled to mature on varying dates within one year.

The Company's investments are reflected at fair market value, which approximates amortized cost. During fiscal year 2003, gross realized gains were minimal and there were no gross realized losses. During fiscal year 2002, gross realized gains totaled \$0.2 million and gross realized losses totaled \$0.2 million. In fiscal year 2001, gross realized gains totaled \$0.3 million and gross realized losses totaled \$0.3 million.

NOTE 5. BILLED AND UNBILLED ACCOUNTS RECEIVABLE

Accounts receivable at June 30, 2003 and 2002, consisted of the following:

(\$ IN THOUSANDS)	<u>2003</u>	<u>2002</u>
Billed	\$147,411	\$134,720
Unbilled	81,328	94,615
Allowance for doubtful accounts	<u>(6,013)</u>	<u>(4,622)</u>
	<u>\$222,726</u>	<u>\$224,713</u>

NOTE 6. PROPERTY AND EQUIPMENT

Property and equipment at June 30, 2003 and 2002, consisted of the following:

(\$ IN THOUSANDS)	<u>2003</u>	<u>2002</u>
Owned assets:		
Computer and office equipment	\$67,374	\$65,402
Computer software	44,447	32,735
Furniture and fixtures	20,084	22,859
Leasehold improvements	20,147	11,346
Buildings	4,202	4,354
Other	<u>5,121</u>	<u>974</u>
	161,375	137,670
Less: accumulated depreciation	<u>(99,836)</u>	<u>(90,536)</u>
	<u>\$61,539</u>	<u>\$47,134</u>
Assets held under capital lease:		
Computer software	525	525
Less: accumulated amortization	<u>(140)</u>	<u>(35)</u>
	<u>385</u>	<u>490</u>
	<u>\$61,924</u>	<u>\$47,624</u>

Depreciation and amortization expense relating to property and equipment was \$20.2 million, \$17.9 million, and \$20.6 million, for the years ended June 30, 2003, 2002, and 2001, respectively. Depreciation expense for the year ended June 30, 2001 includes \$0.9 million of accelerated depreciation due to changes in the estimated useful lives of leasehold improvements on abandoned leased facilities.

NOTE 7. RESTRUCTURING CHARGES

During the three-month periods ended June 30, 2003 and December 31, 2002 the Company recorded facilities-related restructuring charges totaling \$3.5 million and \$5.9 million, respectively, as a result of changes in prior assumptions regarding certain leased facilities which were abandoned as part of the Company's June 2001 restructuring. The changes in prior assumptions were caused by a further deterioration in challenging real estate market conditions, which made it difficult to sub-lease the abandoned facilities at previously estimated rental rates.

In June 2001, the Company made certain reasonable assumptions based upon market conditions, which indicated that sub-lease payments for these abandoned facilities were probable. The June 2001 restructuring charge involved fourteen properties. The Company has been successful in exiting or subleasing eleven of those properties. After significant effort in trying to sub-lease the remaining properties in a time of a declining commercial real estate market, it became apparent to the Company during fiscal year 2003 that the original assumptions for the remaining three properties were no longer valid under current market conditions.

The Company did not record any restructuring provisions in fiscal year 2002.

During the quarter ended June 30, 2001, the Company recorded restructuring and other charges totaling \$7.2 million. These charges included \$3.1 million of employee severance and related costs for eliminating approximately 125 managerial and staff positions worldwide (44% in the U.S. and 56% in Continental Europe), \$3.9 million related to consolidation and abandonment of certain facilities (40% in the U.S. and 60% in Continental Europe), and approximately \$0.2 million primarily related to miscellaneous costs associated with the Company's fourth quarter restructuring plan. Additionally, the Company recorded restructuring benefits of \$0.7 million during the first quarter of fiscal 2001. This consisted of a \$1.5 million reduction in previously accrued restructuring charges due to changes in estimates related to the third quarter 2000 restructuring, offset by \$0.8 million for exiting a consulting business location in the U.S.

During the three months ended March 31, 2000, the Company announced that Novartis, a key client, reduced the amount of work outsourced to the CRS business segment, due to Novartis' reprioritization of its research projects. As a result, the Company estimated that total revenue for fiscal year 2000 and 2001 would be reduced by \$50 to \$55 million in the aggregate. Consequently, during the year ended June 30, 2000, the Company recorded restructuring and other charges of \$13.1 million. These charges included \$7.2 million for employee severance costs related to the Company's decision to eliminate approximately 475 managerial and staff positions in order to reduce personnel costs as a result of a material dollar volume of contract cancellations. The charges also included \$4.3 million for lease termination costs related to continued efforts to consolidate certain facilities and reduce excess space in certain locations, in addition to a benefit derived from a change in the Company's original estimate of when certain facilities would be sublet. The remaining charges, totaling \$1.6 million, primarily related to the write-off of certain intangible assets and other investments, which were not expected to produce future value.

Fiscal years 2003, 2002, and 2001 activities against the restructuring accrual were as follows and are recorded under accrued restructuring charges in the Company's Consolidated Balance Sheet:

(\$ IN THOUSANDS)

	Balance at June 30, 2002	Gross Provisions	Payments/ Adjustments	Balance at June 30, 2003
Employee severance costs	\$1,176	-	\$(932)	\$244
Facilities related charge	2,125	9,374	(2,993)	8,506
	<u>\$3,301</u>	<u>\$9,374</u>	<u>\$(3,925)</u>	<u>\$8,750</u>
	Balance at June 30, 2001	Gross Provisions	Payments/ Adjustments	Balance at June 30, 2002
Employee severance costs	\$2,785	-	\$(1,609)	\$1,176
Facilities related charge	5,709	-	(3,584)	2,125
Other charges	242	-	(242)	-
	<u>\$8,736</u>	<u>-</u>	<u>\$(5,435)</u>	<u>\$3,301</u>
	Balance at June 30, 2000	Gross Provisions	Payments/ Adjustments	Balance at June 30, 2001
Employee severance costs	\$4,183	\$3,070	\$(4,468)	\$2,785
Facilities related charge	4,976	3,891	(3,158)	5,709
Other charges	(15)	269	(12)	242
	<u>\$9,144</u>	<u>\$7,230</u>	<u>\$(7,638)</u>	<u>\$8,736</u>

NOTE 8. CREDIT ARRANGEMENTS

The Company has a line of credit with ABN AMRO Bank, NV in the amount of Euro 12.0 million. This line-of-credit is not collateralized, is payable on demand, and bears interest at a rate ranging between 3% to 5%. The Company primarily entered into this line-of-credit to facilitate business transactions with the bank. At June 30, 2003, the Company had approximately Euro 12.0 million available under this line-of-credit.

The Company has other foreign lines-of-credit with banks totaling approximately \$1.7 million. These lines are used as overdraft protection and bear interest at rates ranging from 4% to 6%. The lines of credit are payable on demand and are supported by PAREXEL International Corporation. At June 30, 2003, the Company had approximately \$1.7 million available credit under these arrangements.

NOTE 9. STOCKHOLDERS' EQUITY

As of June 30, 2003 and 2002, there were 5,000,000 shares of preferred stock, \$0.01 par value, authorized. Of the total shares authorized, 50,000 shares have been designated as Series A Junior Participating Preferred Stock, but none were issued or outstanding. Preferred stock may be issued at the discretion of the Board of Directors (without stockholder approval) with such designations, rights and preferences as the Board of Directors may determine.

In September 1999, the Board of Directors approved a stock repurchase program authorizing the purchase of up to \$20 million of the Company's common stock. Repurchases are made in the open market subject to market conditions. The Company did not repurchase any of its common stock during fiscal years ended June 30, 2003 and 2002. During the fiscal year ended June 30, 2001, the Company acquired 210,000 shares at a total cost of \$1.8 million.

2003 Preferred Stock Rights

On March 27, 2003, the Company adopted a Shareholder Rights Plan. Under this Plan, one Right for each outstanding share was distributed to stockholders of record as of April 7, 2003. The Rights trade with the underlying common stock and initially are not exercisable. Subject to limited exceptions, the Rights will become exercisable if a person or a group acquires 20 percent or more of the Company's common stock or commences a tender offer for 20 percent or more of the Company's outstanding stock. If the Rights become exercisable, the type and amount of securities receivable upon exercise of each Right will depend on the circumstances at the time of exercise. Each Right will initially entitle each stockholder to purchase one one-thousandth of a share of newly created Series A Junior Participating Preferred Stock at an exercise price of \$98.00. The adoption of this Plan did not impact the Company's financial position or results of its operations.

NOTE 10. EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of common shares plus the dilutive effect of outstanding stock options and shares issuable under the employee stock purchase plan. Approximately 1.9 million, 1.2 million, 3.6 million outstanding stock options were excluded from the calculation of diluted earnings per share for the fiscal years ended June 30, 2003, 2002 and 2001, respectively, because they were anti-dilutive.

The following table is a summary of shares used in calculating basic and diluted earnings per share:

(IN THOUSANDS)	Years ended June 30,		
	2003	2002	2001
Net income (loss)	\$10,662	\$13,235	\$(825)
Weighted average number of shares outstanding, used in computing basic earnings per share	25,371	24,928	24,637
Dilutive common stock options	<u>312</u>	<u>654</u>	<u>-</u>
Weighted average shares used in computing diluted earnings per share	<u>25,683</u>	<u>25,582</u>	<u>24,637</u>
Basic earnings (loss) per share	\$0.42	\$0.53	\$(0.03)
Diluted earnings (loss) per share	\$0.42	\$0.52	\$(0.03)

NOTE 11. STOCK AND EMPLOYEE BENEFIT PLANS

The Stock Option Committee of the Board of Directors is responsible for administration of the Company's stock option plans and determines the term of each option, the option exercise price, the number of option shares granted, and the rate at which options become exercisable.

2001 Stock Incentive Plan

In September 2001, the Company adopted the 2001 Stock Incentive Plan, ("2001 Plan") which provides for the grant of incentive and non-qualified stock options for the purchase of up to an aggregate of 1,000,000 shares of common stock to employees, officers, directors, consultants, and advisors (and any individuals who have accepted an offer for employment) of the Company. Options under the 2001 Plan expire in ten years from the date of grant and the vesting period may vary at the board of directors' discretion.

1998 Stock Plan

In February 1998, the Company adopted the 1998 Non-qualified, Non-officer Stock Option Plan (the "1998 Plan") which provides for the grant of non-qualified options to purchase up to an aggregate of 500,000 shares of common stock to any employee or consultant of the Company who is not an executive officer or director of the Company. In January 1999, the Company's Board of Directors approved an increase in the number of shares issuable under the 1998 Plan to 1,500,000 shares. Options under the 1998 Plan expire in eight years from the date of grant and vest at dates ranging from the issuance date to five years.

1995 Stock Plan

The 1995 Stock Plan ("1995 Plan") provides for the grant of incentive stock options for the purchase of up to an aggregate of 3,028,674 shares of common stock to directors, officers, employees, and consultants to the Company. Options under the 1995 Plan expire eight years from the date of grant and vest over ninety days to five years.

Employee Stock Purchase Plans

In September 1995, the Company adopted the 1995 Employee Stock Purchase Plan (the "Purchase Plan"). Under the Purchase Plan, employees had the opportunity to purchase common stock at 85% of the average market value on the first or last day of the plan period (as defined by the Purchase Plan), whichever was lower, up to specified limits. An aggregate of 600,000 shares could have been issued under the Purchase Plan. The Purchase Plan terminated in fiscal year 2000.

In March 2000, the Board of Directors of the Company adopted the 2000 Employee Stock Purchase Plan (the "2000 Purchase Plan"). Under the 2000 Purchase Plan, employees have the opportunity to purchase common stock at 85% of the average market value on the first day of each opening period or last day of each purchase period (as defined by the Purchase Plan), whichever is lower, up to specified limits. An aggregate of approximately 800,000 shares may be issued under the 2000 Purchase Plan.

During fiscal year 2003, there were 273,093 shares purchased at a range of \$7.17 to \$10.59 per share and during fiscal year 2002, there were 267,112 shares purchased at a range of \$7.17 to \$11.69 per share.

Stock Options of Subsidiary

In August 2000, Perceptive Informatics, Inc. ("Perceptive"), a majority owned subsidiary of the Company, adopted the 2000 Stock Incentive Plan ("the Plan") to grant rights to purchase up to an aggregate of 7,030,000 shares of Perceptive common stock. Under the Plan, Perceptive may grant to its employees, officers, directors, consultants and advisors, options, restricted stock awards, or other stock-based awards. As of June 30, 2003 and 2002, Perceptive was not publicly traded and the shares outstanding under this plan were 3,200,427 and 3,182,927, respectively.

Summary Data for PAREXEL Stock Option Plans

Aggregate stock option activities for all plans, excluding Perceptive's Plan, for the three years ended June 30, 2003 were as follows:

	Options	Weighted Average Exercise Price
Outstanding at June 30, 2000	2,658,495	\$18.38
Granted	1,400,500	\$11.17
Exercised	(83,297)	\$6.82
Canceled	(381,175)	\$19.27
Outstanding at June 30, 2001	3,594,523	\$15.76
Granted	876,000	\$13.19
Exercised	(130,324)	\$8.41
Canceled	(325,629)	\$17.79
Outstanding at June 30, 2002	4,014,570	\$15.20
Granted	129,000	\$11.19
Exercised	(138,061)	\$9.23
Canceled	(346,148)	\$17.81
Outstanding at June 30, 2003	3,659,361	\$15.05
Exercisable at June 30, 2001	1,292,204	
Exercisable at June 30, 2002	1,830,609	
Exercisable at June 30, 2003	2,251,228	
Available for future grant at June 30, 2003	1,399,269	

Summary information related to options outstanding and exercisable as of June 30, 2003 was as follows:

Outstanding			Options Exercisable		
Range of Exercise Prices	Outstanding as of June 30, 2003	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price	Exercisable as of June 30, 2003	Weighted Average Exercise Price
\$ 0.0000 - \$ 3.7810	28,993	0.8	\$0.01	28,993	\$0.01
\$ 3.7811 - \$ 7.5620	76,000	0.4	\$7.43	76,000	\$7.43
\$ 7.5621 - \$11.3430	1,024,800	4.9	\$9.55	597,449	\$9.58
\$11.3431 - \$15.1240	1,495,292	6.0	\$12.75	554,508	\$12.63
\$15.1241 - \$18.9050	205,975	3.0	\$17.83	175,311	\$18.06
\$18.9051 - \$22.6860	249,741	3.5	\$21.24	240,407	\$21.27
\$22.6861 - \$26.4670	121,010	2.6	\$24.23	121,010	\$24.23
\$26.4671 - \$30.2480	220,050	2.7	\$27.09	220,050	\$27.09
\$30.2481 - \$34.0290	187,000	2.0	\$31.78	187,000	\$31.78
\$34.0291 - \$37.8100	50,500	2.7	\$36.19	50,500	\$36.19
	<u>3,659,361</u>			<u>2,251,228</u>	

401(K) PLAN

The Company sponsors an employee savings plan ("the Plan") as defined by Section 401(k) of the Internal Revenue Code of 1986, as amended. The Plan covers substantially all employees in the U.S. who elect to participate. Participants have the opportunity to invest on a pre-tax basis in a variety of mutual fund options. The Company matches 100% of each participant's voluntary contributions up to 3% of gross salary per payroll period subject to an annual cap of \$3,000. Company contributions vest to the participants in 20% increments for each year of employment and become fully vested after five years of continuous employment. Company contributions to the Plan were \$2.8 million, \$2.6 million and \$2.4 million, for the years ended June 30, 2003, 2002, and 2001, respectively.

NOTE 12. FINANCIAL INSTRUMENTS

As of June 30, 2003 and 2002, the Company had entered into currency exchange contracts to exchange Euro and British Pounds for U.S. dollars. The notional contract amount of outstanding currency exchange contracts were approximately \$28.3 million and \$24.0 million at June 30, 2003 and 2002, respectively.

While it is not the Company's intention to terminate the above derivative financial instruments, fair values were estimated based on market rates, which represented the amounts that the Company would receive or pay if the instruments were terminated at the balance sheet date. The fair values of currency exchange contracts were approximately \$0.2 million at June 30, 2003 and \$0.4 million at June 30, 2002.

At June 30, 2003, maturities of the Company's currency exchange contracts ranged from one to two months.

NOTE 13. INCOME TAXES

Domestic and foreign income (loss) before income taxes for the three years ended June 30, were as follows:

(\$ IN THOUSANDS)	2003	2002	2001
Domestic	\$1,743	\$23,413	\$8,119
Foreign	<u>16,744</u>	<u>(479)</u>	<u>(7,247)</u>
	<u>\$18,487</u>	<u>\$22,934</u>	<u>\$872</u>

Provisions for income taxes for the three years ended June 30, were as follows:

<u>(\$ IN THOUSANDS)</u>	<u>2003</u>	<u>2002</u>	<u>2001</u>
Current:			
Federal	\$5,209	\$8,512	\$4,362
State	1,027	3,060	1,324
Foreign	<u>4,393</u>	<u>2,849</u>	<u>733</u>
	<u>10,629</u>	<u>14,421</u>	<u>6,419</u>
Deferred:			
Federal	(2,714)	(4,351)	(2,088)
State	(409)	(89)	(55)
Foreign	<u>(256)</u>	<u>(968)</u>	<u>(3,033)</u>
	<u>(3,379)</u>	<u>(5,408)</u>	<u>(5,176)</u>
	<u>\$7,250</u>	<u>\$9,013</u>	<u>\$1,243</u>

The Company's consolidated effective income tax rate differed from the U.S. federal statutory income tax rate as set forth below:

<u>(\$ IN THOUSANDS)</u>	<u>2003</u>	<u>%</u>	<u>2002</u>	<u>%</u>	<u>2001</u>	<u>%</u>
Income tax expense computed at the federal statutory rate	\$6,470	35.0%	\$8,027	35.0%	\$305	35.0%
State income taxes, net of federal benefit	408	2.2%	1,989	8.7%	871	100.0%
Foreign rate differential	(956)	-5.2%	(344)	-1.5%	1,406	161.2%
Foreign permanent tax adjustments	(780)	-4.2%	(109)	-0.5%	257	29.5%
U.S. permanent tax adjustments	21	0.1%	(2,928)	-12.8%	(130)	-14.9%
Change in valuation allowances	1,911	10.3%	2,625	11.4%	(2,170)	-248.9%
U.S. separate return limitation year loss	-	-	-	-	-	-
Other	<u>176</u>	<u>1.0%</u>	<u>(247)</u>	<u>-1.1%</u>	<u>704</u>	<u>80.6%</u>
	<u>\$7,250</u>	<u>39.2%</u>	<u>\$9,013</u>	<u>39.3%</u>	<u>\$1,243</u>	<u>142.5%</u>

Provision has not been made for U.S. or additional foreign taxes on undistributed earnings of foreign subsidiaries as those earnings have been permanently reinvested. Such taxes, if any, are not expected to be significant.

Significant components of the Company's net deferred tax assets as of June 30, 2003 and 2002 were as follows:

(\$ IN THOUSANDS)	2003	2002
Deferred tax assets:		
Foreign loss carryforwards	\$8,749	\$7,838
Accrued expenses	25,361	21,521
Allowance for doubtful accounts	484	736
Deferred contract profit	14,840	12,667
Other	81	39
Gross deferred tax assets	49,515	42,801
Deferred tax asset valuation allowance	(11,868)	(9,958)
Total deferred tax assets	37,647	32,843
Deferred tax liabilities:		
Property and equipment	(9,031)	(8,704)
Deferred contract profit	(2,687)	(1,838)
Other	(1,513)	(1,264)
Total deferred tax liabilities	(13,231)	(11,806)
	\$24,416	\$21,037

The net deferred tax assets and liabilities included in the consolidated balance sheets as of June 30, 2003 and 2002 were as follows:

(\$ IN THOUSANDS)	2003	2002
Current deferred tax assets	\$27,604	\$21,642
Non-current deferred tax assets	10,043	11,201
Current deferred tax liabilities	(2,557)	(2,538)
Non-current deferred tax liabilities	(10,674)	(9,268)
	\$24,416	\$21,037

The Company has foreign tax loss carryforwards, tax effected, of approximately \$8.7 million that are available to offset future liabilities for foreign income taxes. Substantially all of the foreign tax losses are carried forward indefinitely, subject to certain limitations. A valuation allowance has been established for certain future foreign income tax benefits related to income tax loss carryforwards and temporary tax adjustments based on an assessment that it is more likely than not that these benefits will not be realized. In fiscal year 2003, the valuation allowance increased by \$1.9 million. As of June 30, 2003, \$11.8 million of future tax rate benefit remains. The ultimate realization of this benefit is dependent upon the generation of sufficient taxable income in respective jurisdictions.

NOTE 14. COMMITMENTS AND CONTINGENCIES

The Company leases its facilities under operating leases that include renewal and escalation clauses. Total rent expense was \$30.2 million, \$25.4 million, and \$23.7 million for fiscal years 2003, 2002 and 2001, respectively. Future minimum lease payments due under non-cancellable leases are as follows:

(\$ IN THOUSANDS)	2004	2005	2006	2007	2008	Thereafter	Total
Operating leases	\$27,666	\$27,439	\$23,434	\$19,510	\$17,708	\$58,054	\$173,811

In association with the FW Pharma acquisition as discussed in Note 3 to the consolidated financial statements included in Item 8 of this annual report, the Company is obligated to make a maximum additional payment of \$4.3 million in contingent purchase price if FW Pharma achieves certain established financial and non-financial targets through January 31, 2005.

NOTE 16. RELATED PARTY TRANSACTIONS

During the years ended June 30, 2003 and 2002, certain members of the Company's Board of Directors were affiliated with certain companies in which PAREXEL made investments in fiscal year 2001. The total sum of all of these investments by PAREXEL was \$0.9 million. During the year ended June 30, 2002 and a portion of the year ended June 30, 2003, a member of the Company's Board of Directors was also a director of one of the Company's customers. Revenue recognized from this customer in fiscal year 2002 was \$16.0 million. The accounts receivable balance at June 30, 2002 from this customer was \$8.6 million. Related party amounts included in accounts receivable were on standard terms and manner of settlement.

NOTE 17. GEOGRAPHIC AND SEGMENT INFORMATION

Financial information by geographic area for the three years ended June 30, 2003, 2002 and 2001 were as follows:

(\$ IN THOUSANDS)	2003	2002	2001
Service revenue:			
United States	\$265,332	\$252,082	\$228,351
United Kingdom	96,183	84,208	62,055
Europe (excluding U.K.)	129,402	87,476	83,896
Japan and Other	21,137	20,552	13,258
	<u>\$512,054</u>	<u>\$444,318</u>	<u>\$387,560</u>
Income (loss) from operations:			
United States	\$8,397	\$18,690	\$6,324
United Kingdom	5,724	7,683	(10,040)
Europe (excluding U.K.)	11,192	(3,852)	(941)
Japan and Other	(4,708)	(2,028)	(2,203)
	<u>\$20,605</u>	<u>\$20,493</u>	<u>\$(6,860)</u>
Tangible Long-lived assets:			
United States	\$2,187	\$2,206	\$2,583
United Kingdom	-	-	-
Europe (excluding U.K.)	3,375	2,484	2,361
Japan and Other	1,065	940	499
	<u>\$6,627</u>	<u>\$6,033</u>	<u>\$5,443</u>

The Company is managed through four business segments, namely, CRS, PCG, MMS and Perceptive. CRS constitutes the Company's core business and includes clinical trials management and biostatistics and data management, as well as related medical advisory and investigator site services. PCG provides technical expertise in such disciplines as clinical pharmacology, regulatory affairs, industry training, publishing, and management consulting. PCG consultants identify alternatives and propose solutions to address clients' product development, registration, and commercialization issues. MMS provides a full spectrum of market development, product development, and targeted communications services in support of product launch. Perceptive provides technology solutions to improve clients' product development and commercialization processes. Perceptive offers a portfolio of services that include the design of web-based portals, IVRS, CTMS, electronic data capture solutions, and medical imaging. Perceptive is a majority-owned subsidiary of the Company. As of June 30, 2003, the Company owned approximately 97.4% of Perceptive.

The Company evaluates its segment performance and allocates resources based on service revenue and gross profit (service revenue less direct costs), while other operating costs are evaluated on a geographical basis. Accordingly, the Company does not include selling, general, and administrative expenses, depreciation and amortization expense, interest income (expense), other income (expense), and income tax expense in segment profitability. The accounting policies of the segments are the same as those described in Note 2 to the consolidated financial statements included in Item 8 of this annual report. Furthermore, the Company attributes revenue to individual countries based upon the number of hours of services performed in the respective countries and inter-segment transactions are not included in service revenue.

The Company evaluates its assets (including long-lived assets) on a geographical basis because it has a global infrastructure supporting all four business segments.

(\$ IN THOUSANDS)	CRS	PCG	MMS	PERCEPTIVE	TOTAL
Service revenue:					
2003	\$312,847	\$100,621	\$73,786	\$24,800	\$512,054
2002	\$261,727	\$97,775	\$64,829	\$19,987	\$444,318
2001	\$240,501	\$80,796	\$54,277	\$11,986	\$387,560
Gross profit on service revenue:					
2003	\$113,488	\$24,657	\$23,957	\$9,644	\$171,746
2002	\$86,607	\$26,309	\$21,365	\$4,114	\$138,395
2001	\$75,164	\$17,185	\$16,930	\$521	\$109,800

REPORT OF INDEPENDENT AUDITORS

To the Board of Directors and Stockholders of PAREXEL International Corporation:

We have audited the accompanying consolidated balance sheets of PAREXEL International Corporation and its subsidiaries as of June 30, 2003 and June 30, 2002 and the related consolidated statements of operations, stockholders' equity, and cash flows for each of the two years in the period ended June 30, 2003. Our audits also included the financial statement schedule listed in the Index at Item 15(a) for the fiscal years ended June 30, 2003 and June 30, 2002. These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. The financial statements of PAREXEL International Corporation for the year ended June 30, 2001 was audited by other auditors whose report dated August 14, 2001 expressed an unqualified opinion on those statements and schedule, prior to the reclassifications made to those financial statements related to the adoption of EITF 01-14, as described in Note 2.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of PAREXEL International Corporation and its subsidiaries at June 30, 2003 and June 30, 2002, and the consolidated results of its operations, stockholders' equity and cash flows for each of the two years in the period ended June 30, 2003 in conformity with accounting principles generally accepted in the United States. We also audited the reclassifications described in Note 2 that were applied to restate the 2001 financials statements. In our opinion such reclassifications are appropriate and have been properly applied. However, we were not engaged to audit, review or apply any procedures to the 2001 financial statements of the Company other than with respect to such reclassifications, accordingly, we do not express an opinion or any other form of assurance on the 2001 financial statements taken as a whole. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole presents fairly in all material respects the information set forth therein.

As discussed in Note 2 to the Consolidated Financial Statements, effective July 1, 2001, the Company adopted Statement of Financial Accounting Standards No. 142 "Goodwill and Other Intangible Assets."

Ernst & Young LLP

Boston, Massachusetts
August 6, 2003

REPORT OF INDEPENDENT AUDITORS

To the Board of Directors and Stockholders of PAREXEL International Corporation:

In our opinion, the consolidated statements of operations, stockholders' equity and cash flows for the year ended June 30, 2001 present fairly, in all material respects, the results of operations and cash flows of PAREXEL International Corporation and its subsidiaries for the year ended June 30, 2001, prior to the revisions related to the adoption of EITF 01-14, further described in Note 2, in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company's management; our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

PricewaterhouseCoopers LLP

Boston, MA

August 14, 2001

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable

ITEM 9A. CONTROLS AND PROCEDURES.

The Company's management, with the participation of the Company's chief executive officer and chief financial officer, evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, the Company's chief executive officer and chief financial officer concluded that, as of June 30, 2003, the Company's disclosure controls and procedures were (1) designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company's chief executive officer and chief financial officer by others within those entities, particularly during the period in which this report was being prepared and (2) effective, in that they provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

No change in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended June 30, 2003 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

Information with respect to this item may be found under the captions "Elections of Directors," "Executive Officers" and "Section 16(a) Beneficial Ownership Reporting Compliance" in the Proxy Statement for the Company's 2003 Annual Meeting of Stockholders. Such information is incorporated herein by reference.

ITEM 11. EXECUTIVE COMPENSATION

Information with respect to this item may be found under the captions "Directors' Compensation," "Compensation Committee Interlocks and Insider Participation," "Executive Compensation," "Employment Agreements," "Stock Performance Graph" and "Compensation Committee and Committee Report on Executive Compensation" in the Proxy Statement for the Company's 2003 Annual Meeting of Stockholders. Such information is incorporated herein by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Information with respect to this item may be found under the caption "Security Ownership of Certain Beneficial Owners and Management" and "Equity Compensation Plan Information" in the Proxy Statement for the Company's 2003 Annual Meeting of Stockholders. Such information is incorporated herein by reference.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Information with respect to this item may be found under the captions "Certain Relationships and Related Transactions" in the Proxy Statement for the Company's 2003 Annual Meeting of Stockholders. Such information is incorporated herein by reference.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Information with respect to this item may be found under the caption "Audit Fees" in the Proxy Statement for the Company's 2003 Annual Meeting of Stockholders. Such information is incorporated herein by reference.

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K

(A) The following documents are filed as part of this report:

(1) **FINANCIAL STATEMENTS.** The following financial statements and supplementary data are included in Item 8 of this annual report.

<u>FINANCIAL STATEMENTS</u>	<u>FORM 10-K PAGES</u>
Report of Independent Auditors for the year ended June 30, 2003 and 2002	55
Report of Independent Accountants for the years ended June 30, 2001	56
Consolidated Statements of Operations for each of the three years ended June 30, 2003, 2002, and 2001	34
Consolidated Balance Sheets at June 30, 2003 and 2002	35
Consolidated Statements of Stockholders' Equity for each of the three years ended June 30, 2003, 2002, and 2001	36
Consolidated Statements of Cash Flows for each of the three years ended June 30, 2003, 2002, and 2001	37-38
Notes to Consolidated Financial Statements	39-54

Financial Statement Schedules and Exhibits to the Form 10-K have been included only with the copies of the Form 10-K filed with the SEC. A copy of this Form 10-K, including a list of the Financial Statement Schedules and Exhibits is available free of charge upon written request to: Investor Relations, PAREXEL International, 195 West Street, Waltham, MA 02451.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PAREXEL INTERNATIONAL CORPORATION

By: /s/ Josef H. von Rickenbach

Dated: September 15, 2003

Josef H. von Rickenbach

Chairman of the Board and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signatures	Title(s)	Date
<u>/s/ Josef H. von Rickenbach</u> Josef H. von Rickenbach	Chairman of the Board and Chief Executive Officer (principal executive officer)	September 15, 2003
<u>/s/ James F. Winschel, Jr.</u> James F. Winschel, Jr.	Senior Vice President and Chief Financial Officer (principal financial and accounting officer)	September 15, 2003
<u>/s/ A. Dana Callow, Jr.</u> A. Dana Callow, Jr.	Director	September 15, 2003
<u>/s/ A. Joseph Eagle</u> A. Joseph Eagle	Director	September 15, 2003
<u>/s/ Patrick J. Fortune</u> Patrick J. Fortune	Director	September 15, 2003
<u>/s/ Richard L. Love</u> Richard L. Love	Director	September 15, 2003
<u>/s/ Serge Okun</u> Serge Okun	Director	September 15, 2003
<u>/s/ William U. Parfet</u> William U. Parfet	Director	September 15, 2003

CERTIFICATION

I, Josef H. von Rickenbach, certify that:

1. I have reviewed this annual report on Form 10-K of PAREXEL International Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) [Paragraph omitted in accordance with SEC transition instructions contained in SEC Release 34-47986].
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: September 15, 2003

/s/ Josef H. von Rickenbach
Josef H. von Rickenbach
Chairman of the Board and Chief Executive Officer
(principal executive officer)

CERTIFICATION

I, James F. Winschel, Jr., certify that:

1. I have reviewed this annual report on Form 10-K of PAREXEL International Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) [Paragraph omitted in accordance with SEC transition instructions contained in SEC Release 34-47986].
 - b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: September 15, 2003

/s/ James F. Winschel, Jr.
James F. Winschel, Jr.
Senior Vice President and Chief Financial Officer
(principal financial officer)

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report on Form 10-K of PAREXEL International Corporation (the "Company") for the period ended June 30, 2003 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Josef H. von Rickenbach, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: September 15, 2003

/s/ Josef H. von Rickenbach

Josef H. von Rickenbach

Chairman of the Board and Chief Executive Officer

The certification set forth above is being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Form 10-K or as a separate disclosure document of the Company or the certifying officer.

A signed original of this written statement required by Section 906 has been provided to PAREXEL International Corporation and will be retained by PAREXEL International Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report on Form 10-K of PAREXEL International Corporation (the "Company") for the period ended June 30, 2003 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, James F. Winschel, Jr., Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: September 15, 2003

/s/ James F. Winschel, Jr.
James F. Winschel, Jr.
Senior Vice President and Chief Financial Officer

The certification set forth above is being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Form 10-K or as a separate disclosure document of the Company or the certifying officer.

A signed original of this written statement required by Section 906 has been provided to PAREXEL International Corporation and will be retained by PAREXEL International Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

This Page Intentionally Left Blank.

CORPORATE INFORMATION

PAREXEL

International Corporation
195 West Street
Waltham, Massachusetts
02451-1163
Telephone: (781) 487-9900
Facsimile: (781) 487-0525
Website: www.parexel.com

ANNUAL MEETING

The 2003 Annual Meeting of Stockholders will be held at 1:00 p.m. on Tuesday, November 11, 2003 at the Museum of Our National Heritage, Lexington, MA.

STOCK LISTING

Nasdaq National Market
Symbol: PRXL

FINANCIAL REPORTS

Copies of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as other investor materials, are available at no charge upon request from:

PAREXEL

International Corporation
Investor Relations
195 West Street
Waltham, Massachusetts
02451-1163
Telephone: (781) 434-4118
Facsimile: (781) 487-9931

TRANSFER AGENT AND REGISTRAR

EquiServe Trust
Company, N.A.
P.O. Box 43010
Providence, RI 02940-3010
(816) 843-4299
www.equiserve.com

INDEPENDENT ACCOUNTANTS

Ernst & Young
Boston, Massachusetts

LEGAL COUNSEL

Hale and Dorr LLP
Boston, Massachusetts

OFFICE LOCATIONS

North America

Orange, California
San Diego, California
San Mateo, California
Ontario, Canada
Boulder, Colorado
Stamford, Connecticut
Atlanta, Georgia
Chicago, Illinois
Lowell, Massachusetts
Waltham, Massachusetts
Baltimore, Maryland
Rockville, Maryland
Durham, North Carolina
Bedminster, New Jersey
Hackensack, New Jersey
Media, Pennsylvania
Centreville, Virginia

Europe

Wavre, Belgium
Prague, Czech Republic
Hoersholm, Denmark
Espoo, Finland
Levallois-Perret, France
Montpellier, France
Orléans, France
Paris, France
Poitiers, France
Berlin, Germany
Frankfurt, Germany
Freiburg, Germany
Munich, Germany
Budapest, Hungary
Milan, Italy
Vilnius, Lithuania
Amsterdam, Netherlands
Lillestrøm, Norway
Krakow, Poland
Warsaw, Poland
Bucharest, Romania
Moscow, Russia
Barcelona, Spain
Madrid, Spain
Stockholm, Sweden
Kiev, Ukraine
Guildford, United Kingdom
Harrow, United Kingdom
London, United Kingdom
Sheffield, United Kingdom
Worthing, United Kingdom

Asia Pacific/ Middle East/Africa

Sydney, Australia
Tel Aviv, Israel
Kobe, Japan
Tokyo, Japan

Bloemfontein, South Africa
Johannesburg, South Africa

South America

Buenos Aires, Argentina
Sao Paulo, Brazil
Santiago, Chile

FORWARD-LOOKING STATEMENTS

This report contains certain "forward-looking statements" concerning projected future financial performance and expected plans for future operations to assist investors in gaining a better understanding of the Company. For a discussion of factors which could cause results to differ materially from such statements, please refer to the section entitled "Risk Factors" under "Item 1. Business," in the Form 10-K included in this Annual Report.

DIRECTORS AND OFFICERS

BOARD OF DIRECTORS

A. Dana Callow, Jr.
Managing General Partner
Boston Millennia Partners
Executive Chairman
MedAptus, Inc.

A. Joseph Eagle
Chairman
Blackspot Interactive, Ltd.

Patrick J. Fortune, Ph.D.
Partner
Boston Millennia Partners II
Executive Chairman
Knowledge Impact Systems, Inc.

Richard L. Love
Chief Operating Officer
Translational Genomics
Research Institute (TGen)

Serge Okun
Individual Investor
former President and
Chief Executive Officer
IMS International

William U. Parfet
Chairman of the Board and
Chief Executive Officer
MPI Research, Inc.

Josef H. von Rickenbach
Chairman of the Board and
Chief Executive Officer
PAREXEL
International Corporation

OFFICERS

Josef H. von Rickenbach
Chairman of the Board and
Chief Executive Officer

Carl A. Spalding
President and
Chief Operating Officer

James F. Winschel, Jr.
Senior Vice President and
Chief Financial Officer

Michael E. Woehler, Ph.D.
President, Clinical Research
Services

Andrew J. Morffew, Ph.D.
President, PAREXEL
Consulting Group

Andrew L. Smith
President, Medical Marketing
Services

Mark A. Goldberg, M.D.
President, Perceptive
Informatics, Inc.

Susan H. Alexander
Senior Vice President and
General Counsel

Ulf Schneider, Ph.D.
Senior Vice President and
Chief Administrative Officer

Alberto Grignolo, Ph.D.
President, Worldwide
Regulatory Affairs

Ronald F. Tetzlaff, Ph.D.
President, KMI

Michael J. McKelvey, Ph.D.
Senior Vice President,
Worldwide Data Management

Peter Rietman
Vice President and Treasurer

PAREXEL.

PAREXEL International Corporation
195 West Street
Waltham, MA 02451-1163
781.487.9900 t
781.487.0525 f
www.parexel.com